BIOLOCIAL EVALUATION OF MITOCHONDRIA-TARGETING PHOTOSENSTIZERS AND SITE-SPECIFIC PRODRUGS by Rajaputra, Pallavi
 




BIOLOCIAL EVALUATION OF MITOCHONDRIA-TARGETING 





SUBMITTED TO THE GRADUATE FACULTY 
in partial fulfillment of the requirement for the 
Degree of 















BIOLOCIAL EVALUATION OF MITOCHONDRIA-TARGETING 
PHOTOSENSTIZERS AND SITE-SPECIFIC PRODRUGS 
 
A DISSERTATION APPROVED FOR THE 









































































© Copyright by PALLAVI RAJAPUTRA 2013 



























I would like to express sincere gratitude to my advisor, Dr. Youngjae You, for 
his direction, criticism and encouragement, which has seen me through the 
project. I will be forever thankful to him for imparting his knowledge and 
providing me with excellent training. I try to keep his emphasis of perfection 
in my work.  
I would like to thank the chair of my graduate committee Dr. Ann West, for 
her extraordinary direction and advice, my committee members; Dr. George 
Richter-Addo, Dr. Lester Reinke, and Dr. John Moore-Furneaux, for their 
understanding and encouragement throughout the program. 
I would also like to thank the members of the medicinal chemistry laboratory 
both past and present especially Dr. Ethel Ngen who synthesized            
TPP-cations, Mr. Gregory Nkepang who synthesized CMP-cations, and     
Dr. Moses Bio who synthesized the prodrugs. I would like to thank Dr. Bibbin 
Paul for teaching in vivo techniques and for helpful discussion during his 
stay. I would like to thank Dr. Samuel Awuah, Ryan Watley and Vidya 
Biradar for encouragement, scientific and friendly discussions. 
The journals entitled “Synthesis and in vitro biological evaluation of lipophilic 
cation conjugated photosensitizers for targeting mitochondria” (reference # 
173) "Evaluation of delocalized lipophilic cationic dyes as delivery vehicles 
v 
 
for photosensitizers to mitochondria" (reference # 206) were reproduced in 
this dissertation with permission from Elsevier. The journals entitled "Site-
Specific and Far-Red-Light-Activatable Prodrug of Combretastatin A-4 Using 
Photo- Unclick Chemistry" (reference #243 ) were reproduced in this 
dissertation with permission from American Chemical Society. 
I would like thank my friends and family especially my cousin Dr. Suresh 





























Table of contents                                                                                                              
                Page 
List of Abbreviations …………………………………………………………..…xii 
List of Tables ……………………………………………………………………..xiv 
List of Figures ……………………………...……………………………………..xv 
List of Equations………………………………………………………………….xvii 
Abstract …………………………………………………………………………..xviii 
Chapter 1. Introduction …………………………………...…………………….1 
1.2. Photodynamic therapy-mechanism of action………….…….……….........1 
1.3. Important components of PDT ………………………………….…………..3 
1.3.1. Light …………………………………………………….,……….…..3  
1.3.2.  Singlet oxygen ………………………………………..……..….....4 
1.3.3.  Photosensitizers …………………………………….…...….….....5  
  1.3.3.1. First generation PSs  ………………..………….....…….6 
  1.3.3.2. Second generation PSs  ……………………….……….8 
  1.3.3.3. Third generation PSs  …………………………..……….9 
1.4.  Cell killing by PDT:..…………………………………..……………..……..13 
1.4.1. Apoptosis …………………………………………….………….…14  
1.4.2. Autophagy………………………………………………..…..........16 
1.4.3.  Necrosis …………………………………….….………..…..........17  
1.5.  Subcellular targets of PS ………………………..…………………………17 
vii 
 
1.5.1    Nuclei …………………………………….…………….…………18  
1.5.2.   Plasma membrane ……………………..…………………..…...18 
1.5.3.    Lysosomes………………..…………………….….………..…..19  
1.5.4.    Microtubules………………………………………….……….…20  
1.5.5.   Mitochondria……………….…………………………….…..…...21 
1.6.  Mitochondrial targeting in PDT….…………………………………………22 
1.7. Current drug delivery systems ……………….……………..……………..24 
1.7.1. Liposome drug delivery …………………………………………..24  
1.7.2. Polymer drug delivery ………………………………………........25 
1.7.3. Dendrimer drug delivery ……………………………………........26  
1.8. Aim and scope…………………………….……………………………........27 
Chapter 2. In vitro biological evaluation of tetra-nitrogenic  
prophyrin based lipophilic cation conjugated photosensitizers for 
targeting mitochondria .………………………………………………...…......30 
2.1. Introduction ………………………………………………………………….30 
2.2. Hypothesis………………………………………….………………………...35 
2.3. Experimental design ………………………………………………………..36 
2.4.  Experimental procedure……………………………..……………………..38  
2.4.1.   Cells and culture conditions………….……………….………...38  
2.4.2.   Intracellular accumulation…………………….……………..…..38 
2.4.3.   Stability of the ester bond …….....................….….………..….39  
viii 
 
2.4.4.   Dark toxicity…………………………………………….…………40  
2.4.5.   Phototoxicity……………..………………………………..…..….42 
2.4.6.  Sub-cellular localization…………………………………………43 
2.4.7.   Statistical analysis …………………………………………........44 
2.5.  Results and discussion……………………………………………………..46  
2.5.1   Intracellular accumulation……………………..……………..…..46 
2.5.2.   Stability of the ester bond……………………….….………..….48  
2.5.3.   Dark toxicity……………………………………………………….49 
2.5.4.   Phototoxicity .…………………………….…………….………...51 
2.5.5.   Sub-cellular localization……….……………………………..….52 
2.6..  Summary and conclusion………………….………………….…………..55  
2.7.  Further studies…………………………………….…………….…………..55  
Chapter 3.  In vitro biological evaluation of core-modified porphyrin 
lipophilic cation conjugated photosensitizers for targeting 
mitochondria……….…………………..…………………………….…………..56  
3.1.  Introduction………………….………………….…………………….……..56 
3.2.  Experimental section………………………………………………………..59  
3.2.1.  General methods  ……...…………………………….…………..59 
3.2.2.  Photophysical studies …….……….………..……………………59  
ix 
 
 3.2.2.1.   Absorption spectra and molar extinction  
 coefficients……………………..…………………………….……60  
 3.2.2.2   n-Octanol/pH 7.4 buffer partition coefficients …….…60 
 3.2.2.3.  Aggregation tendency of the dyes in a medium…..…61 
 3.2.2.4.  ET in the CMP-Rh conjugate ….…………….………..62 
 3.2.2.5.  Singlet oxygen generation …………………………….63 
 3.2.3.  In vitro studies …………………………………………………….64  
 3.2.3.1.   Cells and culture conditions………….…….………...64 
 3.2.3.2.   Intracellular accumulation…………………..……..….65 
 3.2.3.3.   Dark toxicity………….……………………….………..65  
 3.2.3.4.   Phototoxicity…………………………………….…..….65 
 3.2.3.5.   Sub-cellular localization ……………………………....66 
 3.2.4. In vivo studies…………….………………….…………………….67  
 3.2.4.1.   Animals …….………….…………………………..…...67  
 3.2.4.2.   In vivo biodistribution…………..……………………...68 
3.2.5.   Statistical Analysis ……………..……………………..………...68 
3.3. Results and discussion……………………………………………………..69 
 3.3.1. Photophysical studies…………...………….……………….……69 




 3.3.1.2.  Aggregation tendency of the dyes………………...….71
 3.3.1.3.  Energy transfer in the conjugate CMP-Rh…………..73 
 3.3.1.4.  Singlet oxygen generation.…………………………….75 
 3.3.2.  In vitro studies …………………………………………………….76 
   3.3.2.1.    Cellular uptake… ……………….……….……...…….76 
 3.3.2.2.    Dark toxicity……….……………………….……….….78 
 3.3.2.3.  Phototoxicity…………………………………….…..…..79 
 3.3.2.4.   Sub-cellular localization……………………………….81 
 3.3.3.  In vivo…………….………………….…………………….……….83  
 3.3.3.1    Time- dependent biodistribution of CMP-tPP…….. .83  
3.4.  Summary and conclusion…………….……………...….………...……….85  
Chapter 4.  Biological evaluation of prodrug delivery systems………...86  
4.1.  Introduction…………….………………….…………………….…………..86 
4.2.  Mechanism of action of the anti-cancer drug, linker and photosensitizer 
conjugate……………..…………………...……………………………………....87  
4.3.  Experimental procedure……………………………………………………89  
4.3.1   Cells and culture conditions……………………………………..89 
4.3.2.  Bystander effect by CMP-L-CA4……………….….……….……90  
4.3.3.  Apoptosis assay …………………..…………….………..………91  
 4.3.4. Antitumor efficacy studies………………………………………..93 
xi 
 
 4.3.5. Statistical analysis…………………………. …………………….94 
4.4.  Results and discussion……………………………………………………..94  
4.4.1   A bystander effect by CMP-L-CA4… …………………...…..….95 
4.4.2 Apoptosis assay…………………………………………………..97 
              4.4.3   Antitumor efficacy:……………………..………..………………..97 
4.5. Conclusion………………………………………………………………..…101 


















List of Abbreviations 
1O2   Singlet oxygen 
1PS   Singlet state photosensitizer 
3O2   Molecular oxygen or triplet oxygen 
3PS   Triplet state photosensitizer 
CA4   Combretastatin A-4 
CMPLCA4  dithiaporphyrin-linker- Combretastatin A-4  
CMP   Core-modified porphyrin (Dithiaporphyrin) 
DLC  Delocalized lipophilic cation 
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
ER  Endoplasmic reticulum 
ET  Energy transfer 
Fc   Fragment crystallizable 
FRET   Fluorescence resonance energy transfer 
IP   Intraperitoneal 
ISC   Inter-system crossing 
MCF-7  Michigan cancer foundation-7 (human breast adenocarcinoma 
cell line) 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NMR   Nuclear magnetic resonance 
PCI  Photochemical internalization 
xiii 
 
PAMAM  Polyamidoamine 
PBS  Phosphate buffered saline 
PTPC  Permeability transition pore complex 
PDT:   Photodynamic therapy 
PEG   Polyethylene glycol 
PGA   Polylactide-co-glycolide 
PLA   Polylactic acid 
PLGA   Polylactide-co-glycolide 
PS   Photosensitizer 
PCD  Programmed cell death 
Rh-123  Rhodamine-123 
Rh B   Rhodamine B  
ROS  Reactive oxygen species 
SO  Singlet oxygen 
THF  Tetra hydro furan 
tPP  Triphenyl phosphine 








List of Tables 
                                                                                                          Page 
1. UV- vis - near - IR band maxima and extinction coefficients in chloroform &            

















List of Figures 
                                                                                                                  Page 
1. Modified PDT mechanism …………………………………………..………....2 
2. First generation photosensitizers... …………………………………………...8 
3. Second generation photosensitizers……………………………….………....9 
4. Third generation photosensitizers…. ………………………………………..13 
5. Schematics of mitochondrial targeting of DLC……………………………...23 
6. Schematics of scope of the dissertation……………………………………..29 
7. Examples of DLC's ...……………………………………………………….....35 
8. Structure of DLC-conjugated to TPP………………………………………...37 
9. MTT reduction to formazan (MTT Assay)…………………………………...41  
10. Intracellular accumulation of dyes in R3230AC cell………….…..……....47 
11. Stability of the ester group in TPP–Rh....................................................49  
12. Dark toxicities of the respective dyes incubated in R3230AC cells….....50  
13. Phototoxicity of R3230AC cells treated with the respective dyes.……....52 
14. Sub-cellular localization of TPP-OH and TPP-conjugates …….………...54 
15. Structures of DLC-conjugated CMPs ……………………………….……..58 
16. DPBF oxidation by singlet oxygen via [2+4] cycloaddition……………….63 
17. Absorption spectra of compounds at 2 µM in CHCl3…………….……….69 
18. Fluorescence emission from the dyes…………………………..………….73 
19. Fluorescence spectra of CMP-Rh, CMP-OH, and Rh B………………….74 
20. DPBF oxidation by singlet  oxygen generation……………………...…….76 
xvi 
 
21. Intracellular accumulation of the dyes in Colon 26 cells……………….…78 
22. Dark toxicities of the respective dyes incubated in Colon 26 cells….......79 
23. Phototoxicity of Colon 26 cells treated with the respective dyes…….….80 
24. Sub-cellular localization of the conjugates………………………………...82 
25. Tissue distribution of  CMP-Monocation……………………….…….…….84 
26. Mechanism of release of anti-cancer drug…………………………………87 
27. Structure of compounds………………………………………………..……89 
28. Bystander effect of CMPLCA4……………………………………….…..…95 
29. Apoptosis assay…………………………….………………………….……..95 
30. Schematics for in vivo PDT………………………………………………….97 
31. In vivo efficacy………………………………………………………….….….99 
32. Mice bearing tumors treated with different compounds…....…….……..100 










List of equations 
Equation                                                                                                    Page 
1. Nernst equation………………………………………………………………...30 
2. Modified Nernst equation……………………………………………..……....31 
3. Intracellular accumulation of dyes ……………………………..…….……...39 
4. Cellular amount of dye... ………………………………………….................39 
5. Cell survival (MTT Assay)……………………………………………………..42 
6. Student t-test……………………………………………………………………44 
7. Variance equation……………………………………………………………...44 
8. Q-test equation…………………………………………………………………45 
9. Hill (Sigmoid Emax) equation………………………….……………………….46 
10. Beer-Lambert law ……………………………………………………………60 
11. Aggregation tendency………………………………………………………..61 











Abstract   
This dissertation focuses on two different delivery mechanisms utilizing the 
principle of PDT with a goal to enhance the availability of the cytotoxic agent 
at the tumor site.  
In one approach, which utilizes the higher mitochondrial membrane potential 
of cancerous cell mitochondria over the normal cell, compounds containing 
cations will be delivered to cancer cell mitochondria specifically. Delocalized 
lipophilic cationic dyes conjugated with porphyrin were used to improve the 
delivery of photosensitizer to mitochondria. Tetranitrogenic porphyrin, which 
absorbs around 650 nm, and either rhodamine B or acridine orange were 
used as porphyrin and cations. Due to their fluorescence properties, most of 
these dyes were visualized using fluorescence microscopy to confirm the 
mitochondrial localization. Uptake, photo and dark toxicity were then 
explored. 
In a continuing project, core modified porphyrin photosensitizers with near IR 
absorption (690nm), high singlet oxygen quantum yield and known 
mitochondrial localizing cationic dyes like rhodamine B and triphenyl 
phosphene were explored. The photophysical properties of the conjugates 
like UV absorption, fluorescence, lipophilicity, singlet oxygen generation, and 
FRET efficiency were studied. Once it was confirmed that conjugation with 
cations did not alter the photophysical and singlet oxygen (SO) generation 
capacity of the dyes, biological evaluation was performed. All of these dyes, 
xix 
 
due to their fluorescence properties, were visualized using fluorescence 
microscopy to confirm mitochondrial localization. Uptake and photo and dark 
toxicity were explored. In vivo biodistribution studies show that the cation 
conjugated compound accumulated more in the tumor when compared to the 
photosensitizer itself. 
In a different approach (of delivery), the site-specific delivery of porphyrin-
anti-cancer prodrug conjugate to deliver and activate anti-cancer drug only at 
the tumor site was explored. Biological evaluation of these compounds was 
carried out to see that the concept works under in vitro conditions by 
exposing only a region of cells. Upon successful PDT the anti cancer drug 
was released to cause cell destruction. Once the concept was proved in vitro,     
in vivo studies were performed to see the anti tumor efficacy of the drugs. 
Additionally, the mechanism of cell death was also studied.  
Overall, with this dissertation, the goal of delivering the cytotoxic agent to the 




Chapter 1. Introduction 
The objective of cancer research these days is to develop treatment methods 
to reduce side effects in treatment. Cancer is a group of cells that divide 
without control1; whereas normal cells divide and die at a regular fashion.  
Several approaches are implemented for cancer treatment like surgery, 
irradiation, immunotherapy, hormone therapy, and chemotherapy. Though 
widely used, chemotherapy is limited due to its non-specific action on both 
normal and diseased cells. Current research is focused on developing 
targeted therapies that are more specific to cancer cells and leave normal 
cells to be unharmed. Photodynamic therapy (PDT) is one such modality 
where specificity could be achieved by both preferential accumulation of 
photosensitizers and precise activation with light only at the tumor site.    
 
1.2. Photodynamic therapy-mechanism of action 
PDT is a minimally (or non-)invasive technique that involves a 
pharmacologically inert agent called a photosensitizer (PS), light, and 
oxygen.2, 3 Initially a PS is administered either intravenously, intraperitonially 
or topically. After the PS gets cleared from unaffected tissue, a light made 
either with light emitting diode (LED) or some kind of laser, which can emit 
light of near IR wavelength, is shined upon the affected region. Upon 
irradiation with light, the PS absorbs a photon and goes from ground state to 
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a singlet excited state (1PS). Then via intersystem crossing (ISC) the 1PS 
attains a triplet state (3PS). At the triplet state the PS is not stable and follows 
one of three fates – type I, type II or emitting phosphorescence1. In the Type 
I mechanism, either a hydrogen-atom abstraction or electron-transfer 
between the PS and a substrate occurs, yielding highly reactive free radicals 
and radical ions which generate superoxide anions or hydroxyl radicals. In 
the Type II mechanism, an energy transfer step converts the ground state 
triplet oxygen to singlet oxygen.4, 5 Both Type I and Type II products are 
highly toxic and react with the nearby biological molecules to carry out 
cytotoxicity.2, 6  
 





1.3. Important components of PDT 
Three photochemical reactants form the heart of PDT: 1) light, 2) singlet 
oxygen and 3) photosensitizer. 
 
1.3.1. Light 
Light sources used in PDT are primarily categorized as laser and non-laser 
light sources.9 Broadband light sources like xenon arch lamps or light 
sources equipped with filters were used to eliminate light of short 
wavelength.  Their relative low cost, reliability and simplicity made lamps a 
good choice in PDT.10 However, due to low light intensity and poor coupling 
efficiency into mono fibers, lamps are not the best choice to be used as 
optical fibers. High intensity power output (to avoid tissue attenuation), 
monochromatic character, no thermal effect, and flexibility to couple with fiber 
optics for endoscopic light delivery make lasers commonly used light 
sources.   
Light interaction and penetration into tissue depends on the wavelength and 
the intended treatment volume. Not all wavelengths of light are 
advantageous in PDT. Most of the incident light is absorbed by components 
of blood at in vivo conditions. Hemoglobin can absorb light around 425, 544, 
and 577 nm hence the need for light > 600 nm to ensure significant amounts 
of light.11 Photon energy at wavelengths < 850-900 nm light may not be high 
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enough to activate triplet oxygen (3O2). For wavelengths > 1200 nm, light 
absorption by water molecules are significantly high. Hence wavelengths 
between 600-800 nm are designated as the "therapeutic window" in clinical 
PDT.12  
 
1.3.2. Singlet oxygen 
At ground state, oxygen is in the triplet configuration (3O2). The excited state 
configuration, singlet oxygen (1O2) is the main cytotoxic agent involved in 
biochemical reactions. Generation of singlet oxygen occurs due to the 
interaction of an excited PS in triplet state and ground state molecular 
oxygen. The quantum yield of singlet oxygen depends on three factors. 1) 
the triplet state quantum yield of the PS (0.2-0.9),13 2) quenchers, and 3) 
yield of singlet oxygen per collision (0.2 to 0.7).14, 15   
The lifespan of singlet oxygen (SO) is thought to be 10-40 ns in cells (ranges 
between 10-100 µs in organic solvents16), and its diffusion distance is 10-20 
nm17(no larger in diameter than the cell membrane). Due to its short lifespan 
and diffusion distance the site of PDT damage is the site where there is 
higher concentration of PS.18-20 The tissue lifetime of triplet state of PS      
(10 µs)21, 22 is sufficient enough to convert molecular oxygen to singlet 
oxygen.23, 24 Further, oxygen concentration is most critical in PDT. Normal 
tissue contains about 5% oxygen where as the hypoxic region of the tumor 
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contains < 1% oxygen.25 Hence it can be easily understood that PDT is not 
efficient at hypoxic conditions .   
 
1.3.3. Photosensitizers 
A non-toxic compound which gets activated by absorbing light of particular 
wavelength is called a PS. Upon absorbing light, it reaches an excited singlet 
state (1S). Later via a intersystem crossing (ISC) PS reaches a triplet state 
(3PS) and further transfers energy to molecular oxygen, and converts it to a 
cytotoxic reactive oxygen species (ROS)3. Most PSs possess tetrapyrollic 
macrocycles similar to heme or chlorophyll molecules.  
Though not yet clearly known, why certain PSs accumulate preferentially in 
the tumor the following physiological properties of tumor could be an 
explanation. Tumor specific properties such as large abundance of lipids to 
allow retention of lipophilic dyes,26, presence of leaky vasculature, large 
interstitial stromal space to allow easy flow of large molecules, compromised 
lymphatic system to allow the retention of lipophilic compounds,27 low pH 
levels that allow protonation of anionic PS imparting lipophilicity for their easy 
uptake,3 availability of tumor associated macrophages to swallow lipophilic 
PSs,28 presence of newly formed collagen that bind to porphyrins29 are some 
properties implicated for the preferential accumulation of PSs into the tumor.  
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PSs are broadly categorized into three groups based on their chemical 
structure:28 1) Porphyrin based, (for example famous Photofrin. Most of the 
current clinically approved PS fall under this category), 2) Chlorophyll based 
(such as chlorins and bacterochlorins), and 3) Dye based (such as 
phthalocynanins).. 
 
1.3.3.1. First generation PSs 
Porfimer sodium  (HpD, a hematoporphyrin derivative) is a first-generation 
PS. The dawn of modern day PDT began with the development of HpD by 
Lipson and Schwartz in 1960.29 HpD was further purified in the 1970 through 
80's and was called the drug Photofrin®. HpD shows some notable physical 
limitations such as it is not a pure compound but is a mixture of compounds 
made of variable composition, absorbs at lower wavelength (630 nm) and 
molar extinction coefficient of 3,000 M-1 cm-1 on electronic spectrum hence 
requires higher dose and high light intensity for treatment. Although clinically 
approved against several types of cancers, HpD shows some clinical draw 
backs such as  long term skin phototoxicity (up to 6 weeks) post treatment, 
poor selectivity in tumor cells and non-specific binding to normal cells can 
cause damage.30, 31 As a result of the above physical and clinical 




An ideal PS32 should have the following physical properties such as; 1) be 
pure, characterized to be a single compound, 2) be an efficient producer of 
SO, 3) absorb at wavelengths > 650 nm, 4) have high extinction coefficient, 
5) possess longer triplet state life time. It should have the following biological 
properties such as; 1) show minimum or no toxicity without light, 2) should 
preferentially accumulate and retain in area of interest, and  3) exhibit low 
systemic toxicity by being rapidly excreted from the body..   
A few other compounds obtained from natural sources like chlorins, 
bacterochlorins and porphyrins also fall under first generation PS33      
(Figure 2).  However, they face some drawbacks. 5-Aminolevulinic acid 
(ALA) gets metabolized to protoprophyrin IX. But not all tissues produce 
protoporphyrin IX. Protoporphyrin IX absorbs at lower wavelength of 635 nm 
and has an extinction coefficient of 5,000 M-1 cm-1.2 Although, chlorins 
absorb at 660nm and bacteriochlorins absorb at 750-800 nm, they get re-




Figure 2. First generation photosensitizers 
 
1.3.3.2. Second generation PS 
While no PS is believed to have all the properties of an ideal PS, a number of 
second generation PSs with enhanced photophysical and photosensitizing 
properties have been developed. Several PSs such as benzoporphyris, 
chlorins, phthalocyanines, napthalocyanines, methylene blue, hypericins and 
hypocerillins were studied to overcome the drawbacks of Photofrin.35 





Figure 3. Second generation photosensitizers 
 
1.3.3.3.Third generation PSs 
Derived from the second generation PSs, third generation PSs were made by 
attaching them to targeting vectors to specifically deliver PSs to particular 
cells.36 Non-specific storage of PSs in healthy cells has been a major reason 
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for drawbacks such as skin photosensitivity in PDT.37-40  Some targeting 
vectors coupled with PS are amino acids, polymers, proteins, carbohydrates, 
antibodies against tumor specific antigens, and carrier inclusion complexes.36 
New methodologies to exclusively deliver PSs to tumor cells have been 
explored. These methodologies generally utilize differences in both molecular 
and physiological properties between cancerous (tumor) and normal cells 
(tissue). Some of these properties are high vascularization of tumor tissue, 
over expressed cell surface receptors, high metabolic rate of cancerous cells, 
and involvement of enzymes in the activation of PS prodrugs.  
Vascular targeting has gained considerable interest recently.41, 42 Tumor 
tissue displays physiological variations compared to those of normal tissue, 
due to the complex vasculature, imbalance in pro and anti-angiogenic 
factors, and high interstitial pressure. These variations include rapid 
proliferation rate, enhanced permeability, asymmetric branching, lack of 
pericytes and basement membrane coverage.39 Compared to traditional 
approaches for targeting tumor cells, targeting tumor vasculature is much 
easier, more efficient, and has a lower probability of developing drug 
resistance.40 Vascular targeting in PDT could be either passive or active.40 In 
passive targeting, rapid proliferative blood vessels help retain PS. Active 
targeting facilitates covalent coupling of PS to molecules having higher 
affinity to cellular components like integrins, VEGFR and fibronectins.43, 44 
Several PSs, like ethylethipurprin (SnET2), lutetium texaphyrin (Lutex) and 
11 
 
Tookad,39 are known to passively target tumor vasculature.39 Along with the 
supply of nutrients and removal of metabolic wastes, tumor vasculature helps 
maintain exchange of materials between blood plasma and interstitial 
fluids45. The main aim of vascular targeting is to incorporate vascular 
shutdown. Vascular sensitization in PDT causes loss of vascular barrier 
function, which is seen as one of the earliest events.46, 47 Increased vascular 
permeability has been observed after PDT with several PSs46 like 
Verteporfin.48 Although targeting vasculature is very powerful in tumor 
ablation, the heterogeneity of central versus. peripheral vasculature brings 
varying results in tumor destruction. Also, cellular adaptation to hypoxic 
stress might result in tumor reoccurrence.38   
Another strategy for tumor targeting is through photosensitizer 
immunoconjugates, which recognize cell surface antigen on tumor.44, 49-51 
This strategy provides dual advantages: firstly, activation of PS occurs only in 
presence of light; secondly, immunoconjugates interact with the specific 
antigens present only on tumor cells. Drawbacks associated with this 
strategy are: multiple PS molecules need to be attached to an antibody to 
produce the desired effect, extreme modification could render antibody 
unrecognizable by the antigen, and the immunoconjugate might be 
considered as non-self and destroyed.52 Staneloudi et al. found single-chain 
monoclonal antibody (scFv) fragment more efficient in penetrating tumor 
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masses due to their small size and effective clearance from the circulation 
due to lack of an Fc (fragment crystallizable) domain.51 
A number of delivery vehicles such as microspheres, low density lipoproteins 
(LDL), liposomes, and high molecular weight non-specific carriers such as 
albumin and polyethylene glycols (PEGs), have also been developed to 
transport and release PS to tumor cells.49, 52 Some cancerous cells over 
express folate (KB cells) and LDL receptors. Folate and LDL conjugated PSs 
have been developed to target such receptor positive sites on the tumor cell 
surface.49  
Zheng et al. developed photodynamic molecular beacons (PMBs). PMBs 
constitute a PS conjugated to a quencher via a disease-specific  peptide 
linker. The PSs  effect is suppressed untill it approaches the disease specific 





Figure 4. Third generation photosensitizers 
 
1.4. Cell killing by PDT   
In PDT, tumor or tissue damage is mediated through multiple pathways.      
Firstly, direct cellular damage, where photochemical interactions of PS, light 
and molecular oxygen generate reactive oxygen species (ROS) to induce 
cellular damage and consequent tumor ablation.54 Generated ROS can elicit 
a cascade of events that result in direct cell death by apoptosis/necrosis.55, 56 
Secondly, indirect damage where ROS generated upon excitation of PS by 
light can cause vesicular shutdown and leads to a deficiency of oxygen and 
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nutrients57-59 and/or up regulation of immune regulators of immune system 
such as cytokines and interleukins to elicit an immune response.60-62  
The earliest studied cell death process was necrosis. Later, other forms of 
cell death have been recognized. Cells respond to various signals like injury 
and decide to die via a pathway called programmed cell death (PCD). In 
Type I PCD, cells shrink and chromatin condensation occurs. This method of 
cell death is also called apoptosis. In Type II PCD, enzymatic digestion 
(lysosomal enzymes) removes damaged cellular components in a process 
also called autophagy. In Type III PCD, cell swelling occurs, and the plasma 
membrane loses integrity in a process alternatively called as necrosis. All the 
above pathways allow the elimination of abnormal, unnecessary, and 




Apoptosis is a highly regulated method of programmed cell death that occurs 
due to exposure of cells to heat, chemicals, radiation or stress.63-66 
Alternatively, depletion of nutrients required for the growth of the cell, 
cytokine, and ligands-receptor interactions could also induce apoptosis.67 
Morphological changes like blebbing, cell shrinkage, nuclear fragmentation, 
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chromatin condensation, and chromosomal DNA fragmentation are unique 
events occurring during apoptosis.68  
The cellular power plant mitochondria are quite unique due to their 
involvement in the majority of apoptotic pathways.69-75 In the intrinsic 
pathway, proapoptotic proteins lead to the loss of mitochondrial membrane 
potential causing the opening of permeability transition pore  complex 
(PTPC) on the outer membrane, this releases proteins like cytochrome c, 
second mitochondrial activator of caspases (SMAC), and apoptosis inducing 
factor (AIF) into the cytoplasm. Later cytochrome c along with procaspases, 
form the apoptosome. At this stage, procaspases get activated. Caspase-3, 
also called as executioner caspase, further cleaves many cellular proteins, 
which results in chromatin condensation, DNA fragmentation, and conclusion 
of apoptosis. Alternatively, death receptors on the cell surface when triggered 
recruit additional cytoplasmic proteins to form death inducing signaling 
complex (DISC), which activate caspases-8 and 10 and further activates   
caspase-3.76  
The mechanism of apoptosis gained importance in PDT after it was first 
studied by Agarwal et al.77 in non-adherent cells. PDT induces apoptosis 
both in cultured cells and in vivo conditions.55, 77  Compared to several other 
inhibiting agents, apoptosis in PDT may occur in any stage of the cell  
cycle78, 79 and even after cell cycle arrest.80  The distinctive aspect of 
apoptosis in PDT is its molecular target of PSs as the initial photodamage 
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occurs at the site of PS accumulation.  PSs targeting mitochondria causes 
changes in PTP complex, Bcl-2, bcl-xl, and cardiolipins.81. Mitochondria 
localizing PS such as Verteporfin  induces rapid apoptosis.82 Endoplasmic 
reticulum (ER) targeting PSs damage calcium pumps to release stored 
calcium into cytosol and then into mitochondria81. Lysosomal PSs damage 
the lysosomal membrane releasing cathepsins and hydrolases that activate 
apoptotic mediators like Bid, and further promote mitochondrial apoptosis.76  
 
1.4.2. Autophagy 
Autophagy is a catabolic process to degrade dysfunctional cellular organelles 
or to recycle unnecessary cellular components during starvation to support 
cell survival83.  Cells undergoing autophagy become isolated from rest of the 
cells and form double-membrane enclosed vacuoles called 
autophagosomes, which are then engulfed84 by lysosomes and recycled.85  
At lower doses of PDT, autophagy promotes cell survival, but at higher doses 
cell death occurs.86 Autophagy occurs as a common initial response 
following PDT whether or not apoptosis is blocked.87, 88 Kessel et al. studied 
the role of apoptosis and autophagy following PDT and suggested there 





1.4.3. Necrosis  
Necrosis occurs due to external factors like cytokins, heat, ischemia, heat, 
irradiation, and pathogens90. Necrosis is unregulated, and products of cell 
death are released into the immediate surroundings. The accumulation of 
PSs in plasma membrane at doses high enough to damage components of 
other pathways may cause necrosis.91  
Several factors determine the mechanism of cell death in PDT treated cells. 
At higher concentration, PS induces necrosis, and at lower concentrations, it 
induces apoptosis92-95 The site of localization of PS also plays a key role in 
determining the cell death mechanism. The localization of the PS varies 
based on the time of incubation.96 The initial site of accumulation of few a PS 
may not be the actual damaged site.97 Different reactive species formed at 
the same site may show different cellular responses.98, 99  
 
1.5. Subcellular targets of PS 
SO (1O2) is the cytotoxic agent in PDT. SO has very short lifetime (< 40 ns) 
and small radius of diffusion in biological systems (< 20 nm).17 Hence the 
location of a PS is considered to be the site of photodamage. This section 
will elaborate the significance of different organelles (nuclei, plasma 
membrane, lysosomes, microtubules, endoplasmic reticulum, and 




Due to their hydrophobic nature, most clinically approved PSs accumulate 
either in cytoplasmic membrane or in organelles but not in the nuclei. 
However, a few PSs that target nuclei have been developed and studied. 
Rosenkranz et al. designed peptide conjugates of PSs that showed improved 
cell-specificity, internalization, and possessed ability to escape from 
intracellular vesicles and target nucleus.100 Nuclear targeting of these peptide 
PS conjugates improved the photodynamic activity to about 2500-fold higher 
than that of free PS. However, another study done by Gomer et al. showed 
that cell death due to DNA damage was not as effective when compared to 
damage caused to membranes in PDT.101, 102 
 
1.5.2. Plasma membrane 
The role of the plasma membrane in carrying out cell death in PDT is 
considered inconclusive. Both the plasma membrane targeting PSs 
(Photofrin) and mitochondria targeting PSs (ALA and Pc-4) have shown lack 
of response to growth factors and cytokines,103, 104 This suggests that both 
photo activation of the plasma membrane and oxidative reactions or 
signaling mechanism initiated at the mitochondria can damage it. Lipophilic 
PSs, for example HpD, partition into the phospho lipid bilayer of the plasma 
membrane and hence show membrane damage.105 Such damage is 
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observed only during the initial incubation period (1 h). However after 
prolonged incubation (18 h) with HpD, more intracellular damage to 
lysosomes (discussed in next section) and especially to mitochondria was 
observed.106 Usually, photo damage to plasma membrane has been coupled 
with the necrotic mode of cell death.106, 107. 
 
1.5.3. Lysosomes 
A few PSs are known to localize in lysosomes and induce apoptotic cell 
death. Other PSs like mTHPC108 and ATX-S10109 showed lysosomal 
damage. Few lysosomally bound PSs showed apoptosis due to their 
relocalization into mitochondria.110, 111 Lysosomal damage in PDT was 
associated with cleavage of Bid, release of cytochrome c from mitochondria 
and activation of caspases 9 and 3. NPe6 treated murine hepatoma 1c1c7 
cells showed delay in apoptotic cell death.112 Whereas, Tao cells (derivatives 
of 1c1c7 cells), which are aryl hydrocarbon receptor (AhR) deficient lines, did 
not show any effect to NPe6 treatment.113 When cells with varying AhR levels 
were compared to those with higher levels of AhR, they showed rapid 
cleavage of Bid, activation of caspases and higher rate of apoptosis. Hence, 
though considered to be a critical means for PDT, lysosomal damage was 
later demonstrated to elicit no direct response.  
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Lysosomally accumulated PSs undergo photochemical internalization (PCI), 
a mechanism well studied by Berg et al.114-118 In PCI, PSs are uptaken and 
entrapped into lysosomal vesicles. Upon photoirradiation and disruptive 
action by SO, lysosomally trapped PSs are released and relocate to critical 




Microtubules are a component of the cytoskeleton. They are important in 
maintaining the cell structure, motility, and cell signaling. Due to their 
involvement in separation of duplicate chromosomes during the mitotic cell 
division, microtubules have been a point of interest in cancer therapy.120  
Several PS, have been identified to disorganize microtubules, cause mitotic 
arrest and further leads to the induction of apoptotic cell death.    
Photofrin,121, 122 sulphonated meso-tetraphenylporphyrines,123 and                          
Zinc(II)-phthalocyanine124  were shown to cause cellular inhibition due to 







Generally, drugs interfering with mitochondrial function are known to be more 
effective in killing tumor cells.81 This also holds true in the case of PDT 
agents.81 Of all the intracellular organelles, mitochondria are thought to be 
the most attractive target in PDT.69-71, 125 Mitochondria are called the power 
house of cells due to their involvement in energy production in the form of 
ATP, metabolism, calcium ion signaling, maintaining redox potential, etc.126, 
127 Following mitochondrial photo damage a series of events such as loss of 
mitochondrial membrane potential, and release of proapoptotic factors 
(Smac/Diablo, AIF and cytochorme c) into cytosol, which leads to activation 
of caspases in presence of energy. Following activation of caspases, cell 
death occurs via apoptosis.55, 63 Several models have been suggested to 
explain the mechanism of PDT post mitochondrial damage. One model is the 
PTPC model. This model suggests release of apoptosis related mitochondrial 
factors, mitochondrial proteins located in the mitochondrial intermembrane 
space, and collapse of mitochondrial transmembrane potential occur due to 
opening of PTPC.73, 125, 128-130 PSs targeting mitochondria are commonly 
more efficient than those that do not. Several PSs like Photofrin, 
protoporphyrin IX, zinc phthalocyanine and silicon phthalocyanine have been 
found to affect mitochondrion by chance.131  There is a need for rational 




1.6. Mitochondrial targeting in PDT 
The idea of mitochondrial targeting has its foundations during late 1980's, 
when Chen et al. observed that an enhanced mitochondrial transmembrane 
potential (∆Ψm) is a prevalent tumor cell property.133, 134  Over 200 cell lines, 
including tumorous and normal varieties, were studied, and the authors 
demonstrated that a typical 60 mV higher mitochondrial transmembrane 
potential was observed in tumor cells than in normal cells. Only 2% of cell 
types did not show this characteristic.133, 135 It was also observed that a few 
cationic molecules accumulated preferentially in the cancer cell 
mitochondria.136 This is possible due to the negative plasma transmembrane 
potential (inner side of the cell) and inner mitochondrial transmembrane 
potential on the matrix side of the organelle. Due to the charge, cationic 
compounds were drawn through membrane and accumulated preferentially 
in the mitochondria. Hence, the concept of specific targeting of cancer cells 
through mitochondrial targeting is based on the findings that a large amount 
of cationic compounds tend to preferentially localize and retain in cancerous 
cell mitochondria compared to normal cell mitochondria.137, 138  
The selective localization of cationic compounds can be explained using the 
Nernst equation. According to the Nernst equation, the plasma 
transmembrane potential is normally -60 mV while the mitochondrial 
transmembrane potential is usually -120 mV for normal cells and -180 mV for 










Figure 5. Schematics of mitochondrial targeting of DLCs (extracted and 
modified)139. 
 
Every -60 mV could lead to a 10 fold increase in the accumulation of 
positively charged molecules. Hence, upto a 1000-fold higher accumulation 
in the mitochondria compared to the cytoplasm can occur with molecules 
containing delocalized lipophilic cations (DLCs).134 
Hence, a number of PSs have been developed by conjugating porphyrin 
based PSs (with good photosensitizing properties) to molecules that contain 




1.7. Current Strategies for targeted drug delivery systems 
1.7.1. Liposomal drug delivery 
A liposome is an artificially synthesized encapsulated structure composed of 
an amphiphilic phospholipid bilayer with an aqueous interior.142 Liposomes 
range in a size from 80-100 nm. Liposomes usually consist of phospholipids 
such as phosphatidylcholine and also contain mixed lipid chains with a blend 
of a surface active agent like phosphatidylethanolamine. A liposome consists 
of a lipophilic membrane that encapsulat a region of aqueous solution. This 
prevents the aqueous solution from escaping through the lipid envelope.  
Water insoluble compounds can be dissolved into the lipid membrane, and in 
this way, liposomes can carry both lipophilic molecules and hydrophilic 
molecules.  
Thus using liposomes, compounds can be delivered to cell membranes 
where the liposome fuse with the cell membranes. Otherwise indiffusable 
lipophilic compounds such as DNA and drugs, can be delivered into the cells 
in the form of liposomes. Usually, all liposomes have a hydrophilic layer 
embedded. Although it is not a necessity. Various procedures have been 
followed for the encapsulation, such as a gradient method for vincristine143  
and ammonium sulfate method for doxorubicin.144  Introduction of a 
hydrophilic polymer like polyethylene glycol (PEG) will lower detection by the 
reticuloendothelial system,145 enhance circulation lifetime and prevent 
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interference between liposome and plasma proteins. Nevertheless, 
liposomes still suffer drawbacks suchas complexity in controlling the release 
of drugs from liposomes, extravasation from the blood and binding to cell 
surface receptors.146 
 
1.7.2. Polymer drug delivery 
Synthetic polymers are widely used for targeted drug delivery.147 Most 
commonly used synthetic polymers are the aliphatic polyesters, specifically, 
hydrophobic polylactic acid (PLA), hydrophilic polyglycolic acid (PGA), and 
copolymers polylactide-co-glycolide (PLGA).  
A distinctive characteristic of polymers in drug delivery is their controlled 
release profile spanning from days (PGA) to months (PLA), which can be 
accomplished by modification of the ratio of PLA to PGA.148 Controlled 
release systems aim to improve efficacy by modifying pharmacokinetics and 
the pharmacodynamics of drug149, 150 such as the release profile and capacity 
to cross biological carriers (which depends on the size of the particle), 
biodistribution, clearance, and stability (metabolism). 
In sustained release, the active substance is steadily released with a kinetic 
profile of zero-order; thus the therapeutic effect is retained over a long period 
of time.151  
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Both the sustained and controlled drug release from internalized or localized 
PLGA nanoparticles can be very useful as they offer capability to control the 
rate, duration and amount of intracellular drug concentration. The rate and 
extent of duration of release are important factors in improving efficacy. 
Some polypeptides still have drawbacks in their drug delivery potential such 
as limited sites for conjugation with drug and ineffective sustained release. 
 
1.7.3. Dendrimer drug delivery   
Dendrimers are monodisperse macromolecules with recurring branching 
structures that originat from a central core.152  Drug molecules can be 
entrapped in the labyrinthine core created by the branches.153, 154 
Poly(amidoamine) (PAMAM) is a well known dendrimer for drug delivery. The 
core of PAMAM is a diamine (also known as ethylene diamine). This reacts 
with methyl acrylate, one more diamine making a generation-0 PAMAM. 
Successive reactions can generate higher generation PAMAM with varying 
properties. The PAMAM core is used as a drug reservoir and has been used 
for delivery of small molecules.153, 155 Upon conjugation with other chemical 
species onto the dendrimer, surface, they act as targeting molecules (for 
example folic acid for targeting tumors).156 Dendrimers have served as 
multivalent systems due to their large number of functional groups. Along 
with use as drug delivery tools, dendrimers are also conjugated to prostate-
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antigen-specific antibodies for targeting the prostate157  and peptides for 
targeting vascular endothelium158  and intestinal epithelium.159 
Even though dendrimeric drug delivery improves selectivity and stability of 
therapeutic agents, there are still limitations such as uptake by the 
reticuloendothelial system, leakage of the drug, exert immunogenic 
response, hemolytic toxicity, and hydrophobicity.160 
 
1.8 Aim and scope 
Current research scientists are in search for new methods to better cure 
cancer. One such new therapeutic modality is photodynamic therapy.  PDT is 
a localized therapy in which an administered photosensitizer generates 
reactive oxygen species (ROS) upon excitation with red light. Even though 
PDT has become an established treatment for a variety of diseases, its 
clinical application remains narrow because of drawbacks of the so far used 
PDT agents or drugs. In order to improve the acceptability of PDT, several 
strategies including the development of third-generation photosensitizers with 
more favorable properties and combination with anticancer drugs are being 
investigated. The goals of this dissertation project were to develop new or 
improve upon existing photosensitizers.   
Overall, this dissertation investigates ways of improving the photodynamic 
response of photosensitizers. Two approaches to deliver photosensitizers 
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were investigated: 1) using DLC dyes to exploit membrane potential 
differences between the cytoplasm and the mitochondria in delivering 
photosensitizers specifically to the mitochondria. 2) using photosensitizer- 
anticancer drug prodrug system where the two are connected via a singlet 
oxygen cleavable bond to deliver and release anti-cancer drug only at the 
tumor region. (Figure 6)  
This dissertation is divided into three distinct projects with each having their 
own objective. These include: 
1) To evaluate the potential of tetranitrogenic porphyrin (TPP)-cation 
conjugates to serve as mitochondria delivery vehicles for photosensitizers. 
2) To evaluate the potential of core-modified porphyrin (CMP)-cation 
conjugates to serve as mitochondria delivery vehicles for photosensitizers. 
3) To evaluate the potential of prodrug system to provide site-specific release 





Figure 6. Schematics of scope of the dissertation showing the two 








Chapter 2. In vitro biological evaluation of tetra nitrogenic prophyrin 
based lipophilic cation conjugated photosensitizers for targeting 
mitochondria 
2.1. Introduction 
A functional mitochondrion has a membrane potential difference across the 
membrane.133  Under in vitro conditions a maximum potential difference of 
~180 mV has been recorded across the mitochondrial membrane.135 Due to 
this  potential difference, molecules with delocalized lipophilic cations 
navigate through the inner mitochondrial membrane and localize in the 
negative mitochondrial interior.  The selective localization of cationic 
compounds can be explained using the Nernst equation. The plasma 
transmembrane potential is normally -60 mV while the mitochondrial 
transmembrane potential is usually -120 mV for normal cells and -180 mV for 
cancerous cells.133 
The Nernst equation describes the ratio of cations accumulated in the 
mitochondria in response to those outside as follows.     
    (1) 
Where ∆Ψm  is the membrane potential difference, R is the gas constant 





(96485.34 Cmol-1), Z is the valence or charge, and A is the chemical activity 
of the ions inside and outside the mitochondria respectively.  
A more simplified form of the above equation for monovalent cation at 37 °C, 
considering the chemical activity and concentration as follows:  
    (2) 
Every -60 mV leads to a 10 fold increase in the accumulation of positively 
charged molecules. Hence, up to thousand fold higher accumulation into the 
mitochondria as compared to the cytoplasm can occur with molecules 
containing delocalized lipophilic cations.134 However these maximum 
concentration are rarely achieved in most biological systems, they could be 
achieved with proper design of molecules.161 
In order for maximum mitochondrial accumulation of these selected cationic 
dyes, the mechanism of mitochondrial targeting must be the predominant 
mode of subcellular distribution. One such process that might prohibit 
mitochondrial localization is lipophilic partitioning136. In order to achieve high 
tumor cell selectivity, the lipophilicity of the cationic dye must be low enough 
to prevent any contributions arising form lipophilic partitioning as this can 
compete with the transmembrane potential guided mitochondrial localization 




cells vs. normal cell will decrease significantly;136  consequently, loss of 
selectivity may occur. Accumulation of the dye into other organelles may 
occur with equal efficiency.138, 162-164  Hence, the accumulation of lipophilic 
cationic compound into the mitochondria of tumor cells will be hypothetically 
possible only if the transmembrane potential-driven processes are greater 
than that of the process of lipophilic partitioning or any other competing 
subcellular distribution mechanism.136  
Keeping the above criteria into consideration, several delocalized lipophilic 
cation containing PS as discussed below have been developed for 
mitochondrial targeting. 
A number of cationic compounds are known to accumulate in the 
mitochondria of cells, yet, only a small sub-class of these compounds are 
recognized to induce the desired photochemical effect in cancerous cells with 
a high degree of specificity.132  Crystal Violet (CV+, Figure 7), belonging to 
the class of cationic triarylmethanes (TAM+), is a relatively low toxicity 
compound.165  It has been used in a variety of medicinal applications such as 
antihelmintics, antiseptics, and for treatment of umbilical cords of 
newborns,166  as well as an antifungal to treat both topical and vaginal 
infections caused by Candida.167  CV+ localizes in the mitochondria and then 
kills the tumor cells (HT-29).138  
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Ethyl Violet (EV+, Figure 7) is another cation which is a known cytotoxic 
agent. Indig and colleagues have demonstrated EV+ accumulates both in 
mitochondria and lysosomes of both normal (CV-1) and cancerous cells 
(MES-SA)138. Furthermore, the cytotoxicity observed is due to a combination 
of mitochondrial damage and subcellular toxic events.138  However, the 
studies involving both CV+ and EV+ were of high importance, as they disclose 
that only compounds localizing in mitochondria exclusively can induce the 
cytotoxicity of tumor cells with high level of selectivity. Further, these 
researchers identified that compounds processing a lipophilic/hydrophilic 
property similar to that of the mitochondrial specific probe Rhodamine-123 
(Rh-123) are effectively up taken by cancer cells in huge amounts and 
demonstrate selectivity to cancer cells168.  
Rh-123 is an affiliate of a class of dyes (rhodamines) well-known to 
accumulate in mitochondria of cells. Due to its high fluorescence properties, 
Rh-123 is commonly used as a biological probe in fluorescence microscopy. 
This was the first compound to be identified as a mitochondrial probe by 
Chen and colleagues.133, 134, 169   Rh-123 accumulates and is retained for a 
longer time in tumor cells vs. normal cells. The means of cellular uptake and 
sub cellular localization into mitochondria of Rh-123 is controlled chiefly by 
transmembrane potential.133, 134 It was also noticed that the compound 
passes directly into mitochondria without staining any of the organelles like 
plasma membrane, nuclear envelope, lysosomes, endoplasmic reticulum or 
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Golgi apparatus.170  Due to easy mitochondrial uptake and retention, low 
cellular toxicity and high fluorescing nature makes Rh-123 a great choice by 
a lot of researchers. However, it shows poor photosensitizing properties.171  
Further, several other PSs have been evaluated for mitochondiral targeting. 
To list some cyanines, xanthenes, phenothiazinium, triarylmethanes, 
chalcogenapyryliums, oxazines, and thiopyrylium dyes171. Despite their 
specificity in localizing into mitochondria they suffer several drawback: 
instability in vivo, low absorbance's in the NIR region and poor quantum 
yields for singlet oxygen generation172.  Hence, a number of photosensitizers 
have been developed by conjugating porphyrin-based photosensitizers with 
good photosensitizing properties to DLC containing molecules for 





Figure 7. Examples of DLCs 
 
2.2. Hypothesis 
It can be hypothesized that a porphyrin-based photosensitizers tethered to a 
DLC containing dye via short aliphatic linker system would deliver the 
photosensitizer to the mitochondria by taking advantage of the mitochondrial 
membrane potential difference, finally improving the photodynamic effect. 




The choice of Rhodamine B was because it contains a DLC and could be 
easily conjugated to a porphyrin by esterification. Furthermore, derivatives of 
rhodamine, such as rhodamine 123, have been shown to specifically 
accumulate in the mitochondria by utilizing the property of mitochondrial 
membrane potential difference.133 
The second dye, Acridine orange, was a choice due to its ease of 
conjugation to a porphyrin by alkylation to obtain a quaternary amine, similar 
to nonyl acridine orange173. Nonyl acridine orange, a known cardiolipin 
specific moiety, has been demonstrated to favor mitochondrial localization.126  
Hence, along with taking advantage of the mitochondrial membrane potential 
difference, acridine orange-porphyrin conjugates might also bind to 
cardiolipin, to further enhance mitochondrial uptake.  
 
2.3. Experimental design 
The synthesis and evaluation of the photophysical properties of the two 
conjugates was done by Dr. Ethel Ngen.173  Briefly, a porphyrin–rhodamine B 
conjugate (TPP–Rh) and a porphyrin-acridine orange conjugate (TPP–AO), 
each possessing a single delocalized lipophilic cation, were synthesized. The 
conjugates were synthesized by conjugating a monohydroxy porphyrin (TPP-
OH) to rhodamine B (Rh B) and acridine orange base (AO), respectively, via 





Figure 8.  Structures of DLC-conjugated to TPP173   
 
To evaluate the efficiency of the conjugates as photosensitizers, their 
photophysical properties and in vitro photodynamic activities were studied in 
comparison to those of TPP-OH, the parent porphyrin photosensitizer. 





2.4. Experimental procedure 
2.4.1. Cells and culture conditions 
The rodent mammary adenocarcinoma cell line (R3230AC) was used for all 
biological experiments. All reagents and culture media were obtained from 
Invitrogen and Sigma-Aldrich. The cells were maintained in minimum 
essential medium (α-MEM) supplemented with 10% bovine growth serum, 50 
units/mL penicillin G, 50 µg/mL streptomycin and 1.0 µg/mL Fungizone. The 
cells were incubated at 37 °C in 5% CO2 using a Sanyo MCO-18AIC-UV 
incubator. The cells were sub-cultured biweekly to maintain the cells at 
approximately 80% confluency. The dyes in all studies except for in vivo 
studies were initially dissolved in DMSO to make a 2 mM stock solution. For 
in vivo studies samples were prepared in a mixture of 1% Tween 80 and 5% 
dextrose solution174. A Lab-line Barnstead International orbital shaker was 
used for all phototoxicity tests and a Molecular Devices SpectraMax M2 
microplate reader was used to read UV/Vis absorbance's. Either an 
Edinburgh Instruments F900 spectrophotometer or a Molecular Devices 
SpectraMax M2 microplate reader was used to read the fluorescence. 
 
2.4.2. Intracellular accumulation 
Dye concentrations in cells were determined using the fluorescence 
intensities of the dyes at appropriate excitation and emission wavelengths, 
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following the procedures in our previous reports.175, 176 Briefly, 2 mM 
porphyrins stock solutions were prepared by dissolving the appropriate amount of 
the respective dyes in DMSO. The stock solutions were diluted to the appropriate 
concentrations with complete media immediately before the addition to cells. 10 μL 
of the respective dilute solutions were then added to 190 μL of complete media in 
each well and the well plates incubated for 24 h. After incubation, the medium was 
removed and the R3230 cell monolayer was rinsed twice with a 0.9% NaCl solution. 
50 μL of DMSO was then added to solubilize the cells and the fluorescence from the 
porphyrins was read using a fluorescence multi-well plate reader (Molecular 
Devices, SpectraMax M2 model) set at the appropriate excitation and emission 
wavelengths. The intracellular porphyrin concentrations were then determined from 
a standard fluorescence curve obtained by dissolving porphyrin standards in DMSO 
to obtain dilute solutions. Results were expressed in fmol/cell. 
 
   (3) 
   (4) 
 
2.4.3. Stability of the ester bond of TPP-Rh in culture media with cells 
The cells were seeded at 2.0 - 3.0 × 104 cells/well complete media using 96 
well plates and incubated for 24 h. The dye stock solutions were then diluted 
to the appropriate concentrations with complete media, and added to the 
40 
 
cells. The cells were incubated for 24 h, after which the medium was 
removed and the cell monolayer was rinsed twice with a 0.9% NaCl solution. 
DMSO (1900 µL) was then added to disrupt the cells and the fluorescence 
was read at λex = 550 nm and λem = 650 nm. The fluorescence spectra of 
TPP-Rh in the cell lysate (DMSO digested) was compared to the spectra 
obtained for  TPP-Rh in DMSO . The ratio of the 580 nm and 650 nm 
fluorescence peaks of TPP-Rh in the cell lysate was also compared to that of 
TPP-Rh in DMSO. 
 
2.4.4. Dark toxicity 
The cells were treated and cell viability was determined as described in our 
previous reports.175, 176 Porphyrin stocks solutions (2 mM), prepared by 
dissolving the appropriate amounts of the respective dyes in 1.5 mL of 
DMSO, were then diluted to the appropriate concentrations in complete 
media immediately before addition to cells. 10 μL of the respective dilute 
solutions was then added to 190 μL of complete media in each well and the 
well plates incubated for 24 h. The medium was then removed and the cell 
monolayer rinsed twice with 190 μL of a 0.9 % NaCl solution. Clear medium, 
with neither phenol red nor bovine growth serum, was then added to the 
wells and the well plates kept in the dark for 1 h. After this the clear medium 
was removed and 190 μL of complete medium added. The cultures were 
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then incubated at 37 °C in 5 % CO2, for 24 h, after which the cell viability 
was determined by MTT assay MTT assay is a colorimetric assay which 
measures enzyme activity in living cells, thus is used in determining cell 
viability after treatment with cytotoxic agents. MTT (3- (4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide), is a yellow tetrazole which upon 
reduction by reductases present in the mitochondria of living cells, is 
converted to a purple formazan salt.  
 
Figure 9. MTT reduction to formazan (MTT Assay) 
On the day of assay a 10 uL of a 10 mg/mL solution of MTT prepared in PBS 
was added to 190 uL of complete media in the wells and the cells incubated 
for 4 h. The solutions were then removed and the cell pellets dissolved in 50 
uL of DMSO and the absorbance measured at 570 nm with background 
substraction at 650 nm. The cell viability was then quantified by measuring 
the absorbances of the treated cells, compared to that of the untreated cells 
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(controls) and expressed as a percentage. The controls used in the dark 




The cells were seeded at 1.0 - 1.5 × 104 cells/well in complete media (section 
2.4.1) using 96 well plates then incubated for 24 h. The stock solutions of the 
dyes were then diluted to the appropriate concentrations with complete 
media and added to the cells. The cells were incubated for 24 h. After this 
the medium was removed and the cell monolayer was rinsed twice with 190 
µL of a 0.9% NaCl solution. Clear medium was then added to the wells and 
the well plate was placed on the well plate shaker. The well plate lids were 
removed and the wells were exposed to broadband visible light delivered at 3 
mWcm-2 from a 60 W halogen light source for an hour. The broadband light 
was filtered through a 3.5 cm water filter (400-850 nm) to prevent heating of 
the cells. Uniform irradiation of the entire well plate was achieved by gently 
orbiting the well plate on the shaker. After irradiation, the clear media was 
removed and 190 µL of complete media added to the wells. The cells were 
again incubated for 24 h, after which the cytotoxicity was determined by MTT 
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assay and expressed as a percent of the controls (cells exposed to light in 
the absence of the dyes). 
 
2.4.6. Sub-cellular localization  
Dual staining of each dye with Mitotracker Green (MG, M-7514 from 
Invitrogen Co.) was performed to determine their mitochondrial localization. 
Since both TPP-OH and the conjugates (TPP-Rh and TPP-AO) fluoresce in 
the red region of the optical spectrum, a green filter (Propidium Iodide filter, 
exciter: HQ535/50; emitter: HQ645/75; set: 41005 from Chroma Technology 
Co.) was used to acquire the images. For MG, which fluoresces in the green 
region of the optical spectrum, the images were obtained using a red filter 
(FTC/Bdipy/Fluo3/DiO filter, exciter: HQ480/40; emitter: HQ535/50; set: 
41001 from Chroma Technology Co.). However, because some fluorescence 
from the photosensitizers could be captured with the FTC/Bdipy/Fluo3/DiO 
(green) filter and some of the fluorescence of Mitotracker Green with the 
Propidium Iodide filter (red), the exposure time was carefully monitored to 
avoid/minimize cross contamination from each other. To determine the 
appropriate exposure times, the minimum time required to take an image of 
cells singly stained with MG, TPP-OH, TPP-Rh, or TPP-AO were first 
obtained. The cells were then doubly stained with MG and either TPP-OH, 
TPP-Rh or TPP-AO and images obtained using both the green and red 
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filters. The green and red images were then superimposed, and the regions 
of colocalization appeared as yellow.   
Cells were seeded at 2.0 - 3.0 × 104 cells/well in 24 well plates containing 12 
mm diameter cover slips and then incubated for 24 h. The dyes diluted to the 
appropriate concentrations were then added to the well plates and incubated 
for 8 h. After 7 h, 1µM of Mitotracker Green was added to the cells and the 
cells incubated for 1 more hour. After 8 h, the media was removed and the 
cell monolayer was rinsed three times with 3 mL of complete media.  The 
cover slide was then mounted on a slide and the images taken using a Leica 
DMI4000B fluorescence microscope fitted with a QImaging Fast 1394 
camera and Qcapture processing software. The images were modified for 
better visualization with Adobe Photoshop Element 5.0.  
 
2.4.7. Statistical analyses  
All experiments were done in triplicates at least twice, and statistical 
analyses were performed using the Student's t-test for pairwise comparisons. 
        (6) 
S =
        (7) 
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Where   are the respective means of the different trials, N1 and N2 
are the number of data points in each trial; S1 and S2 are the standard 
deviation within each trial. The calculated t-values were then compared to 
standard t-values obtained from a table at a 95 % confidence level (P-value = 
0.05). Whereas, calculated t-values greater than the standard t-values 
indicated a significant difference between the means calculated t-values less 
than standard t-values indicated no significant difference between the 
means. 
All data outliers were removed after performing a Q-test:  
        (8) 
Where, QN is the calculated Q-value calculated from N data points; Xa is the 
suspected outlier, Xb is the data point closest to suspected outlier (Xa) and R 
is the data range. The calculated Q-values were then compared to standard 
Q-values obtained from a Q-table at a 95 % confidence level (P-value = 
0.05). All calculated Q-values greater than the standard Q-value at the given 
degree of freedom, indicated the presence of an outlier and were discarded, 
while Q-values less than the standard Q-values at the given degree of 




The phototoxicity data was further fitted into the S-Plot software, which is 
based on the Hill (sigmoid Emax) equation, to determine the exact IC50 
values. 
  (9) 
Where Emax is the maximum PDT response, CR is the concentration at a 
given PDT response, and CR 50% is the concentration needed to induce 50 % 
of the maximum response. 
 
2.5. Results and discussion 
2.5.1. Intracellular accumulation 
The conjugates accumulated more compared to the unconjugated dye     
(Figure 8). TPP-AO showed the highest uptake of about 12 times higher than 
TPP-OH with 68.2 vs. 5.6 fmol/cell. TPP-Rh showed an uptake of 8 times 
higher than that of TPP-OH with 44.0 vs. 5.6 fmol/cell. The uptake of TPP-
OH and  Rh B were < 10 fmol/cell. The higher uptake of the conjugates 
compared to the unconjugated dyes could be accredited to the lipophilic 
cation on the compounds and their increased flexibility by the aliphatic linker. 
The lipophilic cation on the compounds might aid in binding to negatively 
charged proteoglycan on cell membrane and diffusion into the cells and the 
mitochondria against the potential gradient.177-180 The increased flexibility of 
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the conjugate may be the reason for the improved uptake partly by 
increasing the entropy of the conjugates.181 Along with that, aggregation of 
the conjugates might also be effected by the flexibility for the higher cellular 
uptake.182  
 
Figure 10. Intracellular accumulation of dyes in R3230AC cells. Cells were 
incubated with the respective dyes (10 µM) for 24 h and the intracellular 
uptake determined from a fluorescence calibration curve. Each data point 






2.5.2. Stability of the ester group of TPP-Rh in culture media with cells  
Since ester bonds can be acted upon by esterases in the cells, the stability of 
the ester bond in TPP-Rh was determined. Signature of fluorescence peaks 
of TPP-Rh was used to study the changes. The fluorescence spectrum of 
TPP-Rh in the cell lysate was similar to that of TPP-Rh in DMSO and 
different from that of an equimolar mixture of TPP-OH and Rh B in DMSO 
(Figure 11). In addition, the ratio of the intensity of the fluorescence peak at 
580 nm to that at 650 nm of TPP-Rh in the cell lysate was similar to that of 
TPP-Rh in DMSO. A ratio of 0.25 was obtained for TPP-Rh in the cell lysate 
and 0.21 for TPP-Rh in DMSO. This signifies that the ester bond might not 
be cleaved in cells unless both cleaved products, TPP and Rh B derivatives, 
are cleared from the cell immediately. This is probably due to steric 
hindrance in the conjugate. As a result, it can be inferred that TPP-Rh, acted 





Figure 11. Stability of the ester group in TPP–Rh: fluorescence spectra of 
TPP–Rh and a mixture of TPP-OH and Rh B in DMSO (each 10 µM) and 
R3230AC cell lysate after incubated with TPP–Rh (10 µM) for 24 h. Samples 
were excited at 550 nm and the fluorescence read from 555 to 750 nm. Two 
Y-axis scales were used to take into account the differences in fluorescence 
intensities of TPP–Rh (Y1: black colored scale) and TPP-OH + Rh B (Y2: red 
colored scale). 
 
2.5.3. Dark toxicity  
No significant dark toxicity was observed in cells treated with up to 20 μM of 
either TPP-Rh, TPP-OH, or Rh B. This was most likely due to their inability to 
generate singlet oxygen in the dark. However minimal dark toxicity was 
observed in cells treated with more than 5 μM of either AO·HCl or TPP-AO 
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(Figure 12). Presumably, it was caused by inherent toxic mechanisms of AO 
such as DNA intercalation and inhibition of protein synthesis.183-188 
 
 
Figure 12. Dark toxicities of the respective dyes incubated in R3230AC cells 
for 24 h at different concentrations. Whereas TPP-OH, TPP–Rh, and Rh B 
were incubated at 20 μM, TPP–AO, and AO-HCl were incubated at 2 μM, 5 
μM, 10 μM and 20 μM and kept in the dark. Each data point represents the 








No significant photo toxicity was observed in cells treated with up to 20 μM of 
either TPP-OH or Rh B and irradiated with a 60 W halogen lamp at               
3 mWcm-2 for an hour (Figures 13). On the other hand, cells treated with 
either TPP-Rh, TPP-AO or AO·HCl and irradiated under the same conditions 
showed significant phototoxicity. AO·HCl showed the highest phototoxicity 
under the above irradiation conditions with an IC50 of 2.29 μM, followed by 
TPP-AO with an IC50 of 3.28 μM and then TPP-Rh with an IC50 of 3.95 μM. 
The absence of phototoxicity observed in the cells treated with up to 20 µM 
of either TPP-OH or Rh B could be attributed to a number of reasons. In 
TPP-OH this might be due to its low intracellular accumulation and formation 
of aggregates in aqueous media. While in Rh B this might be due to low 
intracellular accumulation and low quantum yields for singlet oxygen 
generation. On the other hand, the greater phototoxicity observed with TPP–
Rh and TPP–AO, despite their large size, high lipophilicity, and tendency to 
aggregate in aqueous media, could be attributed to their high intracellular 
accumulation and sub-cellular localization in singlet oxygen-sensitive 
organelles like mitochondria. Although there was no significant generation of 
singlet oxygen under our experimental condition, AO-HCl showed the most 
phototoxic effect. It might be due to the phototoxic effect via type I 




Figure 13. Phototoxicity of R3230AC cells treated with the respective dyes 
and irradiated with a 60W halogen lamp at 3 mWcm-2 for 1 h. Cells were 
incubated with the respective dyes at 1, 2, 5, 10, and 20 µM, respectively, for 
24 h prior to irradiation. Each data point represents the average from three 
separate experiments, error bars are the SEM. 
 
2.5.5. Sub-cellular localization  
Dual staining of each dye with MG (MitoTracker Green) was first performed 
to determine localization in mitochondria. The dual staining of TPP–Rh with 
MG was successful. However, TPP-OH and TPP–AO dual staining with MG 
was not possible due to the overlapping fluorescence of TPP-OH and TPP–
AO with MG. Whereas, for cells stained with 1 µM MG, exposure times of 37 
ms and 5 s were required for the green and red filter, respectively, the 
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following exposure times were required for the other dyes using the green 
and red filters, respectively: 2 µM TPP-OH (5 s and 5 s), 5 µM TPP–Rh (4.5 
s and 330 ms), and 2 µM. 
TPP–AO (40 ms and 2 s). In the dual staining of TPP–Rh with MG, the green 
and red filter could capture fluorescence from MG and TPP–Rh, respectively. 
Exposure times of 23 ms and 230 ms were needed for the green and red 
filter, respectively, which are close to the time scales for taking an image 
from individual staining with each filter. Since dual staining was not 
successful for TPP-OH and TPP–AO with MG, fluorescence images of 
individual staining were used to assess the sub-cellular localization. Both 
TPP–Rh and TPP–AO showed a different localization pattern from that of 
TPP-OH (Figure 14). Whereas TPP-OH seemed to have been accumulated 
in localized vesicles in the peri-nuclear area (Figure 14b), TPP–Rh was 
distributed throughout the cytoplasm like MG (Figure 14d–f). However, TPP–
AO showed two differences in pattern compared to TPP–Rh and MG (not 
shown). Staining of TPP–AO was more homogeneous throughout cytosol 
and also stained the nucleus, presumably due to interactions with cytosolic 
RNAs and nuclear DNA. In contrast, TPP–Rh and MG showed punctuate 
staining patterns consistent with mitochondrial localization. TPP– Rh showed 
a very similar staining pattern to MG. This sub-cellular localization of TPP–
Rh was further confirmed by the dual staining studies. From the image 
analysis of the superimposed MG (green filter) and TPP–Rh (red filter) 
54 
 
images, the yellow regions indicate regions of colocalization (Figure 14f). The 
TPP–Rh might be accumulated in mitochondria due to the presence of the 
delocalized lipophilic cation which permitted their accumulation in 
mitochondria. 
 
Figure 14. Sub-cellular localization of TPP-OH and TPP-conjugates: Cells 
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treated with TPP-OH (2 μM) alone: (a) Bright field (50 ms), (b) red filter (5s); 
TPP–Rh (5 μM) + MG (1 μM): (c) bright field (50 ms), (d) green filter (23 ms), 
(e) red filter (230 ms), (f) overlap: bright field (c), green filter (d) and red filter. 
All images were made using R3230A cells after incubated with dye(s) for 8 h 
(TPP-OH, TPP–Rh, and TPP–AO) or 1 h (MG). 
 
2.6. Summary and conclusions 
The biological evaluation of two conjugates, TPP-Rh and TPP-AO, was 
done. The high photo toxicities of the conjugates could be attributed to both 
their high intracellular accumulation and their mitochondrial localization. The 
conjugation of TPP to Rh and AO did improve intracellular uptake and in vitro 
photodynamic activity. In particular, TPP-Rh seemed to preferentially localize 
into mitochondria. Our study suggests that Rh moiety might provide two 
benefits to other photosensitizers: enhanced cellular uptake and 
mitochondrial localization, which are two important subjects in PDT.  
 
2.7. Further studies  
From the above studies Rh shows promising results. Hence preparation of 
Rh conjugates in conjugation with other second generation photosensitizers 




Chapter 3.  In vitro and in vivo biological evaluation of core-modified 
porphyrin lipophilic cation conjugated photosensitizers for targeting 
mitochondria 
3. 1. Introduction  
Photodynamic therapy (PDT) has gained great popularity as a treatment 
modality for both neoplastic and non-neoplastic diseases. A beauty of PDT 
lies in its ability to ablate malignant tissue without systemic toxicity, which is a 
major drawback of traditional methods like chemotherapy and radiotherapy. 
PDT involves an energy transformation from photonic energy (light) to 
chemical energy (reactive singlet oxygen) via a non-toxic photosensitizer. 
Singlet oxygen (1O2) is the principle cytotoxic agent in PDT.2, 190 Due to the 
short lifetime (<0.04 µs) and small radius of diffusion in biological systems 
(<0.02 µm),191 the photosensitizer should be closely located to the target (the 
site of action) damaged by PDT. 
The mitochondrion is a key organelle for cell survival due to its involvement 
in energy production and apoptotic pathways.69-75 Hence, by targeting the 
mitochondria of the cell we may not only achieve apoptotic cell death but also 
maximize PDT effect. A number of photosensitizers have been designed to 
target the mitochondria of a cell for improved PDT treatment.132 A few of 
them are benzoporphyrin-derivatives,192 and delocalized lipophilic cations 
(DLCs) like Rhodamine 123,168 thiopyrylium AA-1,193 Rhodacyanin MKT-
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077.194 One popular targeting strategy is to take advantage of DLCs’ 
tendency of preferential accumulation in mitochondria.126, 141, 195-198 DLCs 
penetrate the hydrophobic layer of plasma and mitochondria membrane and 
accumulate inside the mitochondria. According to the Nernst equation, every 
60 mV difference in membrane potential could lead to 10-fold increase in the 
accumulation of compounds bearing positive charge.197 A maximum of ~ 180 
mV of potential difference has been measured in the mitochondrial 
membrane.135 Theoretically, up to 1000 fold more mitochondrial 
accumulation compared to extracellular fluid could be achieved based on the 
charge on the molecule. 
In our previous work, (Chapter 2) we designed TPP-DLC (TPP: tetraphenyl 
porphyrin & DLC: rhodamine B or acridine orange) conjugates and achieved 
mitochondrial localization and higher cellular uptake by conjugating porphyrin 
to rhodamine.173 We obtained 8 and 14 times higher uptake with the 
conjugate compared to unconjugated porphyrin and rhodamine, respectively. 
Core-modified porphyrins (CMPs) have been extensively studied as second-
generation photosensitizers due to their multiple advantages.199-204 
Especially, the dithiaporphyrins were prepared in a highly pure and well-
characterized form. CMPs can also absorb longer wavelength light (690-710 
nm) than  Photofrin (a clinically approved photosensitizer, 630 nm) and tetra-
pyrrole prophyrins (648 nm)173 and are highly photostable.205 In addition, 
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CMPs showed high singlet oxygen generation quantum yield (Φ(1O2), ~ 0.8) 
making them very efficient PS for PDT treatment.202 
 
Figure 15. Structures of DLC-conjugated CMPs206. 
In the current work, we attempted to develop mitochondria-specific CMP 
conjugates by tethering them to DLCs. Three conjugates were designed such 
as CMP-Rh (a core modified porphyrin-rhodamine B), CMP-tPP (a core 
modified porphyrin-mono-triphenyl phosphonium), and CMP-(tPP)2 (a core 
modified porphyrin-di-triphenyl phosphonium cation)(Figure 15). The choice 
of rhodamine B is mainly due to its effective delivery of photosensitizers 
(tetraphenyl phorphyrin (TPP) and phthalocyanine (Pc)) into the mitochondria 
.173, 207 Triphenyl phosphene (tPP) was chosen since it also improved the 
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mitochondrial uptake of several bioactive compounds by several hundred 
fold.208-211 We prepared both mono- and di-substituted CMP-tPPs to see the 
effect of a number of cations on mitochondrial localization. We envisioned 
that these DLCs deliver the conjugates to mitochondria and thus eventually 
augment the PDT efficiency of CMP. 
The compounds used in this project were contributed by Mr. Gregory 
Nkepang. All the compound were characterized using NMR. I performed the 
photophysical characterization and biological evaluation of the dyes.  
 
3.2. Experimental section 
3.2.1. General methods 
3.2.2. Photophysical studies 
The photophysical properties of the synthesized conjugates and their 
corresponding components were determined in either chloroform or dimethyl 
sulphoxide. Electronic absorption spectra were recorded using either a 
PerkinElmer UV-Vis spectrophotometer (LAMBDA 25). Steady state 
fluorescence spectra were recorded with a PerkinElmer fluorescence 





3.2.2.1. Absorption spectra and molar extinction coefficients 
Dilute solutions of the respective dyes were prepared at appropriate 
concentrations, where the Beer-Lambert law holds true (absorbances less 
than 1 OD). With the exception of rhodamine B (prepared in methanol) all 
other samples were prepared in chloroform. The molar extinction coefficients 
of the respective samples were then calculated from the Beer-Lambert 
equation: 
A = e cl           (10) 
Where A is the absorbance, is the molar absorption coefficient (M-1 cm-1), c 
is the concentration of the solution (M) and l is the path length (cm). All 
experiments were done in triplicates and the results were reported in          
M-1 cm-1. 
 
3.2.2.2. n-Octanol/pH 7.4 buffer partition coefficients 
n-Octanol/water partition coefficients of the dyes were determined by the 
“shake flask” direct measurement method.212 Saturated solutions of the dyes 
were prepared by adding the dyes to a mixture of equal volumes (1 mL) of n-
octanol and a pH 7.4 phosphate buffered saline (PBS). The saturated 
solutions were placed in an ultrasound bath for 30 min, then left to settle for 4 
h. Then, each layer was diluted with chloroform and the absorbance of the 
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dyes in the respective solutions was determined. The partition coefficients 
were then obtained by calculating the ratio of the concentrations of the 
respective dyes in the two layers ([Dye]n-octanol/[Dye]buffer). Results were 
reported as log D7.4 values. 
 
3.2.2.3. Aggregation tendency of the dyes in a medium 
Tendency of the dyes to aggregate in a culture medium was indirectly 
determined by comparing their fluorescence intensities in the culture medium 
to that in DMSO.213 The dyes were dissolved in DMSO (2 mM), diluted to the 
appropriate concentrations with more DMSO, and 10 µL of the diluted 
solution added to 190 μL of either complete media or DMSO in 96 well plates 
to give 10 μM solutions. The plates were then left for an hour after which the 
fluorescence readings were taken at the appropriate excitation and emission 
wavelengths (CMPOH, CMP-tPP, CMP-(tPP)2 excitation 410 nm, emission 
714 nm, CMP-Rh, Rh B excitation 520 nm, emission 590 nm). The change in 
the fluorescence intensities of the dyes in a complete medium compared to 
that in DMSO was then used to estimate the aggregation tendencies of the 
dyes. The results were expressed in arbitrary units. 




3.2.2.4. Energy transfer (ET) in the CMP-Rh conjugate 
Due to the proximity of the two fluorophores, CMP-Rh was expected to act as 
a ET pair where Rh B acts as the donor and CMP acts as acceptor. Thus, it 
was necessary to determine the ET efficiency to estimate the SO generating 
capability of the conjugate. Decrease in fluorescence intensities of the donor 
molecule at specific wavelengths, measured in the presence of the acceptor 
molecule at different distances, was used to demonstrate ET in the 
conjugate.214 A solution of the conjugate (molecules in a close proximity) and 
an equimolar mixture of the conjugate’s individual components CMP-OH and 
Rh B (molecules at a long range) were compared. Stock solutions of the 
CMP-Rh, CMP and Rh B (2 mM) were prepared in tetra hydro furan(THF). 
The compound stock solutions were then diluted with THF to give 1 μM 
solutions. The fluorescence intensities of CMP-Rh and a mixture of CMP-OH 
and Rh B were measured by exciting at 435 nm and 525 nm and the 
fluorescence was measured from 535-650 nm to or 500-750 nm. The 








3.2.2.5. Singlet oxygen generation 
The generation of singlet oxygen by the respective dyes upon irradiation was 
determined indirectly, by measuring the rates of oxidation of                      









Figure 16. DPBF oxidation by singlet oxygen via [2+4] cycloaddition 
Stock solutions of the respective dyes (2 mM) were prepared in DMSO. A 
solution of the respective photosensitizer (5 μM) and DPBF (100 μM) in THF 
were then prepared in culture tubes, so that the 2 mL solutions had not more 
than 2 % (v/v) of DMSO as a cosolvent. The culture tubes were then 
irradiated using 690 ± 10 nm light (LC122-A, LumaCare) for all the dyes at 1 
mWcm-2 for 20 min. Every 2 min, the absorption readings at 414 nm were 




  (12) 
 
3.2.3. In vitro studies 
3.2.3.1. Cells and culture conditions 
Mouse colon cancer cells (Colon 26) or human breast cancer cells (MCF-7) 
were used for all biological experiments. All reagents and culture media were 
obtained from Invitrogen and Sigma-Aldrich. The cells were maintained in 
minimum essential medium (α-MEM) supplemented with 10% bovine growth 
serum, 2mM L-glutamine, 50 units/mL penicillin G, 50 µg/mL streptomycin 
and 1.0 µg/mL fungizone. The cells were incubated at 37 °C in 5 % CO2 
using a Sanyo MCO-18AIC-UV incubator. Colon 26 cells were sub-cultured 
biweekly and MCF-7 cells were sub-cultured once a week to maintain the 
cells at approximately 80 % confluency. The dyes in all studies were initially 
dissolved in DMSO to make a 2 mM stock solution. A Lab-line Barnstead 
International orbital shaker was used for all phototoxicity tests to make more 
homogeneous light exposure. A BioTek® plate reader (SynergyTM 2) was 
used to read UV/Vis absorbance. A Molecular Device fluorescence plate 




3.2.3.2. Intracellular accumulation 
Dye concentrations in cells were determined using the fluorescence 
intensities of the dyes at appropriate excitation and emission wavelengths, 
following the procedures in our previous reports.204, 217 Intracellular 
accumulation at treatment concentrations 10 and 5 µM were determined. 
 
3.2.3.3. Dark toxicity 
The cells were treated and cell viability was determined as described in the 




Colon 26 cells were seeded at 1 - 1.5 × 104 cells/well in 96 well plates then 
incubated for 24 h in 5 % CO2 at 37 o C. The stock solutions of the dyes (2 
mM in DMSO) were diluted to appropriate concentrations with the complete 
medium (see 3.2.3.1) and added to the cells to give final dye concentrations 
(0.25, 0.5, 1, 2, 5 µM). After incubation for 24 h, the medium was removed 
and the cell monolayer was rinsed twice with 190 µL of a 0.9 % NaCl 
solution. The complete medium was then added to the wells and the well 
plate was placed on the well plate shaker. The well plate lids were removed 
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and the wells were exposed to 690 nm diode laser (except Rh B with 540 ± 
10 nm LumaCare) delivered at 5.6 mWcm-2 for 30 min. To achieve more 
uniform irradiation, the entire well plate was gently orbited on the shaker. 
After the irradiation, the cells were again incubated for 24 h, after which the 
cytotoxicity was determined by MTT assay and expressed as a percent of the 
controls (cells exposed to light in the absence of the dyes). 
 
3.2.3.5. Sub-cellular localization 
General procedures for image slide preparation: Cells were seeded at           
2 - 3 × 104 cells/well in 24 well plates containing one 12 mm diameter cover 
slip per well and then incubated for 24 h. The dyes diluted to the appropriate 
concentrations were then added to the well plates and incubated for 14 h. 
[For dual imaging with Rh-123, 2 µM of Rh-123 was added to the cells at 12 
hr time point and the cells incubated for 2 more hours.] After 14 h the media 
was removed and the cell monolayer rinsed three times with 1 mL of PBS 
solution.  The cover slip was then mounted on a slide and the images were 
taken using a Leica DMI4000B fluorescence microscope fitted with a 
QImaging Fast 1394 camera and spot advance version 4.6 processing 
software. The images were processed for better visualization with Adobe 
Photoshop Element 5.0. 
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Dual staining of each dye with Rh-123 (Rhodamine 123, M-7514 from Sigma 
Aldrich) was made to determine their mitochondrial localization. Since both 
CMP-OH and the conjugates (CMP-tPP, CMP-(tPP)2 and CMP-Rh) fluoresce 
in the red region of the optical spectrum, a red filter (Propidium Iodide filter, 
exciter: HQ535/50; emitter: HQ645/75; set: 41005 from Chroma Technology 
Co.) was used to acquire the images. For Rh123, which fluoresces in the 
green region of the optical spectrum, the images were obtained using a 
green filter (FTC/Bdipy/Fluo3/DiO filter, exciter: HQ480/40; emitter: 
HQ535/50; set: 41001 from Chroma Technology Co.). To determine the 
appropriate exposure times, the minimum time required to take an image of 
cells individually stained with Rh-123, CMP-Rh, CMP-tPP, or CMP-(tPP)2 
were obtained from the independent experiments. For dual staining 
experiments, the cells were stained with Rh-123 and either CMP-Rh, CMP-
tPP or CMP-(tPP)2 and images were obtained using both the green and red 
filters. The green and red images were then superimposed, and the regions 
of colocalization appeared as yellow.   
 
3.2.4. In vivo studies 
3.2.4.1. Animals  
Female BALB⁄ c mice were purchased from NCI (Frederick, MD). Mice were 
housed and handled in the animal facility of College of Pharmacy, University 
of Oklahoma Health Sciences Center, Oklahoma City, OK. All animal 
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experiments were approved by IACUC, University of Oklahoma Health 
science Center, Oklahoma City. 
 
3.2.4.2. In vivo biodistribution 
Mice were injected via i.p. with various cations (25 µmol kg-1). At specified 
time intervals (24, 48 and 72 h post injection), the mice (three mice per each 
time point) were euthanized by CO2 inhalation. Tissues were excised from 
major organs and tumor. Collected tissues were rinsed with PBS and blotted 
dry. 100 mg of excised tissues were homogenized with DMSO (1 mL). The 
homogenates were centrifuged at 5160 g for 20 min and then the 
supernatant was used for fluorescence measurement (excitation at 440 nm 
and emission at 720 nm). The amount of compound in each sample was 
determined relative to the standard curve and expressed in ‘‘nmol g-1 tissue’’ 
unit.  
 
3.2.5. Statistical analysis 
Statistical analyses were performed using the Student's t-test for pairwise 
comparisons. A P value of < 0.05 was considered significant. The Hill 






3.3. Results and discussion 
3.3.1. Photophysical studies 
3.3.1.1. Absorption spectra & molar extinction coefficients 
 
Figure 17. Absorption spectra of CMP-OH, CMP-tPP, CMP-(tPP)2, and 
CMP-Rh at 2 µM in CHCl3. 
Three conjugates showed all the characteristic absorption peaks of its 
respective components, indicating that no significant electronic interactions 
might occur at the ground state (Figure 17).218 While absorption maxima and 
extinction coefficient of all the conjugates remained practically the same, the 
extinction coefficients of CMP-OH had much lower molar extinction 
coefficients than those of the others (Table 1). It might indicate some degree 
of aggregation in the ground state.219 There was a slight red shift of Rh B 
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peak from 550 to 558 nm in CMP-Rh as observed in our previous conjugate 
TPP-Rh. This might be due to the proximity of the CMP moiety that seemed 
to change the polarity of the environment of rhodamine moiety, consequently 
















































NA 700 (4.4) 2.01 
Rh B*   
550 
(110.6) 
  2.07 
λmax, nm (µ x 103 M -1cm -1). * In Methanol 
Table 1. UV- vis - near - IR band maxima and extinction coefficients in 
chloroform & n-octanol/pH 7.4 buffer partition coefficients of dyes.  
 
3.3.1.2. Aggregation tendency of the dyes 
Generally, the aggregation tendency of a dye is greatly dependent on various 
factors such as lipophilicity, molecular symmetry, flexibility.219 Aggregation 
usually leads to a dramatic decrease in both fluorescence emission and 
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singlet oxygen generation, consequently decreasing the photodynamic 
activity of photosensitizers.213 High aggregation tendency in a medium could 
be translated to that in the cytoplasm. Consequently, it could cause reduced 
phototoxicity. Although the lipophilicities (Log D7.4) of the dyes are pretty 
close, within 1.79 - 2.04, their aggregation tendencies in the medium showed 
variations (Figure 18). All three conjugates seemed to aggregate more in 
aqueous media and less in DMSO. CMP-OH showed the most severe 
aggregation in the medium, only 2.5% fluorescence emission in the medium 
compared to that in DMSO. This suggests that the aggregation of the 
conjugates could be attributed mostly to the highly planar and rigid structure 
of CMP-OH. However, Rh B and CMP-Rh showed a different aggregation 
pattern, aggregating almost similarly in both medium and DMSO. This is 
probably due to the presence of the rotatable pendent phenyl ring of 




Figure 18. Fluorescence emission from the dyes (10 µM) in both the 
complete medium and DMSO: CMP-OH, CMP-tPP and CMP-(tPP)2 
excitation at 430 nm & emission at 714 nm and  CMP-Rh and Rh B excitation 
at 520 nm and emission at 590 nm. Inset shows an expanded area. 
 
3.3.1.3. Energy transfer in the conjugate CMP-Rh 
Energy transfer (ET), a communication between two chromophores, is a 
possible phenomena when the two chromophores are in proximity. Among 
the three conjugates, only CMP-Rh has two chromophores with a potential of 
ET. We also observed ET between TPP and Rh.173 If there is ET from CMP 
to Rh, it could reduce singlet oxygen generation capability of CMP of the 
CMP-Rh. Thus, to estimate ET we measured fluorescence quenching in 
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three samples: 1) CMP-Rh, 2) CMP-OH (or Rh B), and 3) a mixture of CMP-
OH and Rh B at an equimolar concentration (2 µM). If there is ET, 
fluorescence of excited chromophores should be reduced. Fluorescence 
emission spectra were recorded after irradiation at 435 or 525 nm to excite 
CMP or Rh moiety (Figure 19). 
Figure 19. Fluorescence spectra of CMP-Rh, CMP-OH, and Rh B a) excited 
at 435 nm, b) excited at 525 nm, c) magnified graph of b in the CMP 
emission peak area, and d) ET directions in CMP-Rh. 
Interestingly, when CMP of CMP-Rh was excited at 435 nm, it showed very 
similar CMP emission (λmax, 705 nm) intensity with those of CMP-OH and a 
mixture of CMP-OH and Rh B (Figure 19a). There might be no significant 
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energy loss in CMP-Rh when excited at 435 nm. On the other hand, when 
Rh of CMP-Rh was excited at 525 nm, there was dramatic decrease (~ 80 
%) in fluorescence emission from CMP-Rh compared to those of Rh B and a 
mixture of CMP-OH and Rh B (Figure 19b). In addition, after excitation of the 
Rh group at 525 nm, a significant CMP emission was detected from CMP-Rh 
but not from CMP-OH + Rh B (Figure 19c). There might be a ET from Rh to 
CMP. Since there may not be effective energy transfer from CMP to Rh, it is 
unlikely that singlet oxygen generation capability of CMP in CMP-Rh is 
reduced. 
 
3.3.1.4. Singlet oxygen generation: 
Singlet oxygen generation efficiency of the photosensitizers was evaluated 
using DPBF (1,3-diphenylisobenzofurane), a popular singlet oxygen probe.2 
The rates of DPBF oxidation by all three conjugates were similar to that of 
CMP-OH (Figure 20). Even CMP-Rh and CMP-(tPP)2 showed faster DPBF 
oxidation. In our previous studies, CMPs gave highly effective singlet oxygen 
quantum yields, ~ 0.8.222-224 This indicates all conjugates were able to 
generate singlet oxygen at rates comparable to that of CMP-OH with CMP-
Rh being the most efficient followed by CMP-(tPP)2. No significant DPBF 




Figure 20. Relative rates of DPBF oxidation by singlet oxygen generated 
from the respective dyes irradiated with 690 ± 10 nm light (LC122-A, 
LumaCare) at 1 mWcm-2. 5 μM of the respective dyes were mixed with 100 
μM of DPBF and the mixture irradiated for 20 min. Absorbance readings at 
414 nm were taken every 2 min. 
 
3.3.2 ln vitro studies 
3.3.2.1. Cellular uptake 
Cellular uptake was determined using the fluorescence of the conjugates 
after colon 26 cells were incubated with each conjugate for 24 hr at 5 or 10 
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µM. Interestingly, all three cationic conjugates showed greatly enhanced 
uptake compared to the unconjugated dyes (CMP-OH or Rh B) ) (Figure 21). 
CMP-Rh and CMP-(tPP)2 showed about 7 times and CMP-tPP showed about 
14 times higher than CMP-OH at 10 µM. Similarly, the conjugates CMP-Rh, 
CMP-tPP, CMP-(tPP)2 showed 10.6, 18.9, 8.3 times higher uptake than 
CMP-OH at 5 µM. The higher accumulation of the conjugates compared to 
CMP-OH could be attributed to the delocalized positive charge on the 
molecules and reduced aggregation due to their increased flexibility by the 
aliphatic linker. The delocalized positive charge on the molecules might 
facilitate binding to negatively charged proteoglycan on cell membrane and 
allow diffusion into the cells and the mitochondria against the potential 
gradient.177-180 The increased flexibility of the conjugate might contribute to 
the enhanced uptake at least in part by decreasing the aggregation and 





Figure 21.  Intracellular accumulation of the dyes in Colon 26 cells. Cells 
were incubated with the respective dyes (at 5 or 10 μM) for 24 h and the 
intracellular uptake was determined from a fluorescence standard curve of 
each dye. 
 
3.2.2.2. Dark toxicity 
No significant dark toxicity was observed in cells treated with up to 5 μM of 
CMP-OH, Rh B, tPP or three conjugates (Figure 22). This may probably be 




Figure 22.  Dark toxicities of the respective dyes incubated in Colon 26 cells 
for 24 h at 5 μM concentrations. 
 
3.3.2.3. Phototoxicity 
The conjugates showed greatly increased phototoxicity compared to the 
unconjugated photosensitizer (CMP-OH) (Figure 23). No significant 
phototoxicity was observed in cells treated with up to 5 μM of CMP-OH after 
irradiation with a 690 nm diode laser at 5.6 mWcm-2 for 30 min. On the other 
hand, cells treated with 5 μM of either CMP-Rh, CMP-tPP or CMP-(tPP)2 and 
irradiated under the same condition showed > 70% cell killing. CMP-tPP 
showed the highest phototoxicity under the above irradiation conditions with 
an IC50 of 0.9 µM, followed by CMP-(tPP)2 with an IC50 of 1.67 µM and then 
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CMP-Rh with an IC50 of 2.36 µM. The absence of phototoxicity observed in 
the cells treated with up to 5 µM of CMP-OH could be attributed mainly to 
their low intracellular accumulation (0.19 fmole/cell). Rh B did not show any 
toxicity upto 5 µM as expected, due to its inability to generate singlet oxygen. 
On the other hand, the greater phototoxicity observed with CMP-tPP, CMP-
(tPP)2, and CMP-Rh could be attributed to their high intracellular 
accumulation with effective singlet oxygen generation capability. 
 
Figure 23.  Phototoxicity of Colon 26 cells treated with the respective dyes 
and irradiated with a 690 nm diode laser for all dyes (except Rh B with 540 ± 
10 nm LumaCare) at 5.6 mWcm-2 for 30 min. Cells were incubated with the 
respective dyes at 0.25, 0.5, 1, 2 and 5 μM, respectively for 24 h prior to 
irradiation. Each data point is the average of two independent experiments 
with more than 4 data and error bars are not shown for clarity.  
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3.3.2.4. Sub-cellular localization 
Since the conjugates were designed to target mitochondria, mitochondrial 
localization was estimated using fluorescence dual staining with 
mitochondrial molecular probe, Rhodamine 123 (Figure 24). Green filter 
(excitation 480/40 emission 527/30) was used to obtain signal from 
Rhodamine 123. Red filter (excitation 535/50 emission 645/75) was used to 






Figure 24. Sub-cellular localization of the conjugates: MCF-7 cells treated 
with Rh 123 and one of the conjugates. CMP-Rh + Rh 123 (5 μM + 2 μM) (a) 
Bright field (b) Green filter (c) Red filter, and (d) overlap of (b) and (c); CMP-
tPP + Rh 123 (5 μM + 2 μM) (e) Bright field (f) Green filter (g) Red filter, and 
(h) overlap of (f) and (g); CMP-(tPP)2 + Rh 123 (5 μM + 2 μM) (i) Bright field 
(j) Green filter (k) Red filter, and (l) overlap of (j) and (k).   
CMP-Rh showed a very similar staining pattern to Rh-123 (Figure 24c). 
CMP-Rh was distributed throughout the cytoplasm like Rh-123 (Figure 24b). 
In addition, CMP-Rh and Rh-123 showed punctuate staining patterns 
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consistent with typical mitochondrial probe images. This sub-cellular 
localization of CMP-Rh was further confirmed by the overlapping of the two 
images (Figure 24d), where yellow area present co-localization of CMP-Rh 
and Rh 123. The CMP-Rh might be accumulated in mitochondria due to the 
presence of the delocalized lipophilic cation that facilitated their accumulation 
in mitochondria. On the other hand, CMP-tPP did not show any significant 
staining of mitochondria. Bright CMP fluorescence was detected from edges 
of cells. Very minimal yellowish area was shown (Figure 24h). CMP-(tPP)2 
also showed some degree of mitochondrial localization. More yellowish areas 
(Figure 24l) were shown than CMP-tPP (Figure 24h). However, it was less 
than that of CMP-Rh (Figure 24d).  
 
3.3.3. In vivo studies 
3.3.3.1. Time-dependent biodistribution of CMP-tPP 
In the biodistribution study, liver and spleen exhibited higher accumulation of  
CMP-tPP (Figure 25). Liver tissue, rich in reticuloendothelial system, had 
maximum uptake and retention among the tissues (100 nmol g-1 of tissue at 
24 h post injection). Biodistribution of porphyrins is reported to be associated 
with the number of LDL receptors in respective tissues.174 Organs like liver, 
kidney and lung have elevated number of LDL receptors.174  The tissue 
distribution pattern is consistent with this observation. Liver and kidney 
exhibited higher accumulation of  CMP-tPP. This observation was in 
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accordance with the fact that hydrophobic PDT agents are mostly eliminated 
from the organism via bile-gut pathway.174 The sequence of decrease in 
uptake levels was liver, spleen, lungs, heart, kidney, tumor, skin and muscle. 
This pattern of biodistribution of photosensitizer was similar to Photofrin.174 
The concentrations of CMP-tPP accumulated in tumor at 24, 48 and 72 h 
post injection were 5, 19 and 20 nmol g-1 of tissue, respectively. Tissue 
distribution so far showed  20 nmole/gm of CMP-tPP in tumor and was 
approximately 3 times higher than the unconjugated IY69 (data not shown) 
which showed 7.61 nmole gm-1.174 
 
Figure 25. Tissue distribution of  CMP-tPP: CMP-tPP (25 μmol kg-1) was 
injected i.p. to BALB⁄ c mice. Mice were euthanized at three time points (24, 
48 and 72 h). Tissues were excised and homogenized in DMSO. 
Fluorescence measurements were made with DMSO fraction to determine 























3. Summary and conclusion 
Three conjugates, CMP-Rh, CMP-tPP, and CMP-(tPP)2, were successfully 
synthesized by linking the hydroxy core modified porphyrins (CMP-OH and 
CMP-(OH)2) to either rhodamine B (Rh B) or triphenyl phosphonium (tPP) 
respectively via a saturated hydrocarbon linker in moderate yields. Although 
ET from Rh to CMP was observed in CMP-Rh, it was able to generate singlet 
oxygen at a rate comparable to that of CMP-OH. The conjugation of CMP to 
Rh and tPP did greatly improve intracellular uptake and in vitro photodynamic 
activity compared to CMP-OH. The high phototoxicity of the conjugates could 
be attributed to their intracellular accumulation. Our goal was to deliver CMP 
to mitochondria by conjugating it with DLCs (Rh or tPP). The Rh moiety 
seemed an excellent delivery vector for CMP to mitochondria. The Di tPP 
group also delivered it to mitochondria somewhat but mono tPP group was 
not effective. However, it was not clear from our results if the mitochondrial 
localization can enhance phototoxicity. Although CMP-Rh showed the most 
preferential localization into mitochondria among the three, it was less potent 
than the other two conjugates. The in vivo studies with CMP-tPP showed 






Chapter 4. Biological evaluation of visible/near IR activatable prodrugs   
4.1. Introduction 
A most critical setback of chemotherapy is its non-specific action on healthy 
cells, which creats systemic side effects. New approaches encompassing 
tumor-targeted drug delivery, site-activated pro-drugs, and combination 
therapy have been studied to reduce side effects.225-229 The main goal of any 
methodology is to keep the concentration of drug at a non-toxic level in the 
non-specific sites but above effective concentrations at the tumor sites. PDT 
is a fairly new strategy where otherwise inactive PS can be activated by 
shining light of near IR wavelength to generate SO to regio-selectively kill the 
surrounding tumor cells. In PDT, light can be used to activate the compounds 
for site-specific controlled release of cytotoxic agents. Site-specific release of 
biological moieties using UV and short-visible light230, 231  have been studied 
comprehensively, but of longer wavelengths that can penetrate deep into 
tissue are not common due to a lack of suitable chemistry. Recent advances 
put forward a "smart" approach, which utilizes the properties of 
photosensitization and distinctive chemistry of SO232-235.   
SO in PDT can cleave the unsaturated bond in olefins. Despite this the 
following points have to be considerd to apply this strategy: 1) very few SO 
cleavable linkers, 2) facile synthetic approach, 3) regeneration of unaltered 
parent drug, and 4) translatability into in vivo level. Dr. You et al. have 
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discovered photo-unclick chemistry of aminoacrylate to address all the above 
shortcomings.236  
 
4.2. Mechanism of release of the anti-cancer drug from prodrug 
conjugate 
The prodrug system contains a PS and anti-cancer drug that are connected 
via a SO cleavable bond. Once irradiated with light (690 nm diodelaser). The 
bond is cleaved and anti-cancer drug is released only at the irradiated site 












Figure 26. Mechanism of release of anti-cancer drug from the prodrug 
conjugate. L = Cleavable linker, NCL = Non-cleavable linker 
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A photosensitizer and anti-cancer drug were linked either via a SO cleavable 
olifenic bond or a non-cleavable bond.  CMP is used as the PS. CA-4 or 
Taxol were used as anti-cancer drugs. CA-4 interacts with tubulin and 
prevents its polymerization237 and hence prevents cell division. The choice of 
CA-4 is due to its small size and simple structure and presence of OH on the 
phenolic ring, which helps in forming ester bonds with any molecule. A water-
soluble prodrug of CA-4 (CA-4 phosphate, fosbretabulin) is under clinical 
study for anticancer therapy.  
Taxol is a well known anti-cancer drug.238 Taxol exhibits nanomolar IC50 
under in vitro conditions. Taxol stabilizes the microtubule polymer and 
protects it from dissociation and hence enabls the metaphase chromosomes 
to attain spindle conformation. This blocks the progression of mitosis. Taxol 
induces apoptotic cell death due to extended activation of mitosis or a 
revision of G-phase of cell cycle due to cell division239, 240.  
CMPs were choosen as they have been extensively studied as a second-
generation photosensitizer due to their multiple advantages.204, 222-224, 241, 242 
Especially, the dithiaporphyrins were prepared as a highly pure and well-
characterized form. CMPs absorb longer wavelength light (690-710 nm) and 
are highly photostable205  whereas Photofrin absorbs at 630 nm and 
tetranitrogenic prophyrins absorbs at 648 nm.173 In addition, CMPs showed 
high singlet oxygen generation quantum yield (Φ(1O2), ~ 0.8), which makes 




Figure 27. Structures of compounds.243  
 
Compounds CMP-L-CA4, CMP-NCL-CA4, and CMP-L-Taxol were 
synthesized by Dr. Moses Bio. CA4 and Taxol were obtained commercially. 
 
4.3. Experimental procedure 
4.3.1. Cells and culture conditions 
Mouse colon cancer cells (Colon 26) or human breast cancer cells (MCF-7) 
were used for all biological experiments. All reagents and culture media were 
obtained from Invitrogen and Sigma-Aldrich. The cells were maintained in 
minimum essential medium (α-MEM) supplemented with 10% bovine growth 
serum, 2mM L-glutamine, 50 units/mL penicillin G, 50 µg/mL streptomycin 
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and 1.0 µg/mL fungizone. The cells were incubated at 37 °C in 5 % CO2 
using a Sanyo MCO-18AIC-UV incubator. Colon 26 cells were sub-cultured 
biweekly and MCF-7 cells were sub-cultured once a week to maintain the 
cells at approximately 80 % confluency. The dyes in in vitro studies were 
initially dissolved in DMSO to make a 2 mM stock solution. For in vivo studies 
samples were prepared in a mixture of DMSO, Tween 80 and 5% dextrose 
solution. 
 
4.3.2. Bystander effect by CMP-L-CA4 
Colon 26 cells were seeded at 5,000 cells/ml/well in 24-well plates and then 
incubated for 24 h. Stock solutions (4 mM in DMSO) were diluted with 
medium. The diluted solutions (25 µL) were added to wells (1 mL) to get the 
appropriate final concentrations [CMP-L-CA4 (50 nM) and IY69 (5 μM)]. After 
24 h incubation, the plates were irradiated from the bottom with 
690 nm diode laser at 11 mW/cm2 for 15 min. While irradiating, half of each 
well was blocked with a black masking tape (THORLABS, Cat# T743-1.0) to 
protect cells on the other half of each well. The irradiated plates were 
incubated for an additional 48 h. Then a Calcein AM live cell staining assay 
was performed (from Molecular Probes, Tervigen Cat# 4892-010-K) 
according to the manufacturer supplied standard protocol. Briefly, the cells 
were washed once with the Calcein AM wash buffer (1 mL) and then fresh 
wash buffer (250 mL) and the working reagent (250 mL) were added to the 
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wells. The cells were incubated for 30 min. Fluorescent images were 
obtained with an Olympus IX51 inverted microscope with green fluorescence 
channel to visualize live cells. All images were taken at 10× magnifications. 
 
4.3.3. Apoptosis assay  
On day 0 of the experiment, MCF7 cells (2.0 × 106 cells/well) were seeded in 
a 24 well plates. On day 1, 2 mM DMSO stocks of respective compounds 
were diluted in the media and added into each well to achieve final 
concentrations of 10 uM for all the compounds except IY69. Compound IY69 
was used at a final concentration of 500 nM. The compound seeded cells 
were irradiated on day 1 with 690 nm diode laser for 30 min at 5.6 mW/cm2  
(energy 10.08 J /cm2) without washing the compound. Post irradiation, the 
cells were incubated for another 72 hrs. The day of apoptosis assay, the cell 
monolayer was washed with chilled PBS. The cells were collected by 
trypsinizing with 100 uL of trypsin/EDTA. Harvested cells were centrifuged at 
1200 rpm, 4 oC, for 5 min to obtain the cell pellet. The supernatant was 
discarded and the cell pellet  was suspended in fresh chilled PBS and 
recentrifuged at 1200 rpm, 4 oC, for 5 min. There after, various samples were 
processed in different ways. Untreated cells were suspended either in 100uL 
of 1X Annexin V binding buffer, 100uL of 1X Annexin V binding buffer + 5µL 
of Alexa Fluor® 488 Annexin V or 100 µL of 1X Annexin V binding buffer + 
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1µL of PI, 100uL of 1X Annexin V binding buffer + 5uL of Alexa Fluor® 488 
Annexin V + 1 µL of PI. PDT treated cells were suspended in 100 µL of 1X 
Annexin V binding buffer + 5 µL of Alexa Fluor® 488 Annexin V + 1 µL of PI. 
After addition of the respective reagents the cells were incubated at room 
temperature for 15 min. Just before reading the samples 400 µL of 1X 
Annexin V binding buffer was added.  
Flow cytometric analyses were performed BD AccuriTM C6 Flow Cytometer 
(BD Biosceinces, CA) equipped with an argon-ion laser. Each sample was 
analyzed using 10,000 events/sample acquired in list mode by a Macintosh 
Quadra 650 minicomputer (Apple computer Inc., Cupertino, C). Data analysis 
was performed via three-step procedure using the BD AccuriTM C6 software 
(BD, San Jose, CA). Alexa Fluor® 488 Annexin V was analyzed using 
excitation and emission wavelengths of 488 and 533/30 nm (FL-1 channel); 
PI, 488 and 585/40 nm (FL-2 channel). Debris and clumps were gated out 
using forward and orthogonal light scatter. Detection of phosphatidyl serine 
exposure on the external leaflet of the plasma membrane employing annexin 
V was assayed. This phenomenon is one of the early events in the cascade 






4.3.4. Antitumor efficacy study 
Four- to six-week old female BALB⁄ c mice (18–20 g, Charles River 
Laboratories, Inc.) were used for the murine tumor model. The mice were 
implanted s.c. with 2 × 106 colon 26 cells in PBS (100 µL) on the lower back-
neck region. Tumor growth was monitored with digital caliper. Two 
dimensions l and w (l: the longest axis of tumor and w: the axis perpendicular 
to l) were used to calculate tumor volume (lw2⁄2). Mice with a tumor of the 
diameter 3–5 mm were used for the experiments.  Stock solutions in DMSO 
(4 or 8 mM) and further dilutions in 1% Tween 80 and 5% dextrose solution 
to achieve final doses were as follows: CMP-L-CA4; 4 mM →  2 or 4 
µmole/kg, CMP-NCL-CA4 + CA4; 4 mM → 2 µmole/kg, CMP-L-CA4 + CA4; 
8 mM each → 4 µmole/kg. Samples were filtered using 0.2 µm sterile syringe 
filter. To each mouse, 200 μL of sample was injected via i.p. once a day on 
day 0, 1, and 2. Then, 90 min later mice were anesthetized with ketamine 80 
mg/kg and xylazine 6 mg/kg, i.p. injection. Tumors were irradiated with a 690 
nm diode laser at 200 mW/cm2 for 30 min (360 J/cm2). Tumor size was 
measured with the digital caliper every day after the treatment.   
 
4.3.5. Statistical analysis  
Statistical analyses were performed using the Student's t-test for pairwise 




4.4. Results and discussion:  
4.4.1. A bystander effect by CMP-L-CA4: 
A bystander effect (damage of neighboring cells) was found when CMP-L-
CA4 was irradiated. The cytotoxicity caused was due to the released CA4 
and not by SO in [CMP-L-CA4 + hv] (Figure 28). The SO generated has a 
relatively short lifetime of ~ 40 ns and can diffuse approximately                  
20–200 nm.21, 244, 245 This means PDT cannot generate a bystander effect 
and the SO generated in one cell cannot damage neighboring cells. To study 
the bystander effect of CMP-L-CA4, the left half of each well was irradiated 
and images of the center of the well were obtained. As anticipated, cells in 
the non-irradiated portion where also damaged in a similar manner as the 
irradiated portion due to the bystander effect in CMP-L-CA4 (Figure 28b). 
However, the compound IY69 damaged only the irradiated portion of the 
well217 (Figure 28c). This was because SO generated does not show a 
bystander effect. This evidently confirmed that CMP-L-CA4 killed the cells 






                        
 
Figure 28. Fluorescence live cell images of the center of each well treated 
with (a) control, (b) CMP-L-CA4 (50 nM) and (c) IY69 (5 μM): only the left half 
of each well was irradiated with 690 nm diode laser (11 mW/cm2 for 15 min). 
At these concentrations, CMP-L-CA4 and IY69 did not produce significant 
dark toxicity. 
 
4.4.2. Apoptosis assay 
The apoptotic effect of these prodrug conjugates was further evaluated by 
Annexin V FITC/PI (AV/PI) dual staining assay to examine the occurrence of 
phosphatidylserine externalization and also to understand whether it is due to 
physiological apoptosis or non-specific necrosis. In this study MCF-7 cells 
were treated with various compounds for 72 h at 10 nM concentration, except 




apoptotic effect. It was observed that these compounds showed significant 
apoptosis against MCF-7 cells as shown in Figure 29. Results indicated that 
IY69 showed 5.41%, CMP-L-Taxol showed 10.38%, and CMP-L-CA4 
showed 7.43% of apoptosis, respectively, whereas the standard Taxol and 
CA4 showed 9.31% and 12.32% of apoptosis respectively. From this 
experiment it was suggested that these compounds significantly induce 
apoptosis in MCF-7 cells. 
 
Figure 29. Apoptosis assay. Annexin V-PI staining of MCF-7 cells treated 
with various compounds and irradiated after 24 hr for 30 min with 690 nm 
diode laser. Apoptosis assay was performed 72 hr post-irradiation. D=dead 
cells, L=live cells, A+N=Apoptotic+Necrotic cells, A=Apoptotic cells 
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4.4.3. Antitumor efficacy 
BALB/c mice were subcutaneously inoculated with tumor on the shoulder 
region with colon 26 cells. After the tumor attained 4-6 mm, diameter, various 
compounds were injected. After 1.5 h each tumor was irradiated with 690 nm 
diode laser (360 J/cm2 = 200 mW/cm2 for 30 min) on days 0, 1 and 2. 
 
 
Figure 30.  Schematics for in vivo PDT shows a mice bearing tumor was 
injected with PS and irradiated with laser light. This cause cell death.  
 
Several interesting observations were made. Firstly, the non-irradiated group 
G4 [CMP-L-CA4 + CA4 (4 μmole/kg each)] did not show much difference in 
tumor suppression compared to the untreated group G5 (P > 0.05). The anti-
tumor effects in these groups were negligible in absence of light. Second, 
after irradiation, the G2 [CMP-L-CA4 ] group had a much better (P < 0.05) 
anti-tumor effect than the group (G4) that was not irradiated. Irradiation 
enhanced the anti-tumor efficacy of CMP-L-CA4, possibly due to the release 
98 
 
of CA4 and the PDT effect (CMP moiety + hv). Third, the G3 group [CMP-
NCL-CA4 + CA4 + hv] had a significant (P < 0.05) impediment in tumor 
growth when compared to the control group G5. It might be largely due to the 
result of the PDT effect by CMP-NCL-CA4 + hv because no considerable 
delay occurred in tumor growth with CA4 itself at the same dose in the pilot 
studies. This was consistent with previous report of a minimal antitumor 
effect of CA4 even at a very high dose (506 μmole/kg).246 In addition, signs 
of necrosis were seen on the treated tumors, which are characteristic of the 
PDT effect. The most important group G1[CMP-L-CA4 (2 μmole/kg) + hv] 
showed a significantly (p < 0.05) better antitumor effect than the G3 group 
that was similar to a combination therapy [PDT with CMP-NCL-CA4 plus a 
systemic CA4 (2 μmole/kg each) + hv)]. The enhanced antitumor effect in the 
group G1 may come from the released CA4. Interestingly, no  observe any 
significant acute toxicity in terms of loss in body weight from any group was 




Figure 31. Tumor growth curves. Drug administration: once a day on days 0, 
1, and 2; hv = 360 J/cm2 with 690 nm; 6 mice per group except 3 mice in the 




Figure 32. Mice bearing tumors treated with different compounds and the 
tumor growth pattern comparison on a) day 0 b) day 15. 1) Control, 2) CMP-
L-CA4_4umole/kg, no hv 3) CMP-NCL-CA4_2umole/kg, hv 4) CMP-CL-















Figure 33. Acute toxicity: Body weight change in mice treated with CMP-
NCL-CA4_2umole/kg, hv; CMP-CL-CA4_2umole/kg, hv; 
CMP+CA4_4umole/kg, hv; Control groups    
 
4.5. Conclusion 
This study showed the release of the anti-cancer drug using the principles of 
PDT in biological conditions for the first time. The released CA4 caused the 
bystander effect. All the conjugates showed apoptosis comparable to known 
apoptotic agents. There was no acute toxicity with the conjugated 
compounds. CMP-L-CA4 was most effective in releasing the CA4.  
 
 






















Chapter 5. Conclusion 
Systemic side effects are the main drawback of chemotherapy for cancer 
treatment. Through this dissertation, I tried to address the problem in two 
different approaches utilizing the principles of PDT. PDT is a minimally 
invasive cancer treatment modality with great prospective to selectively 
destroy tumor cells and thus reduce systemic side effects. Nonetheless, PDT 
suffers some inadequacies that need to be tackled to be make it more 
appropriate for clinical use. In developing a good PS one has to consider the 
following factors: the short lifespan of SO in biological systems which is,   
~40 ns and considerably small radius of action, which is ~20 nm. Because of 
this it is important for the PS to localize in the most crucial organelles 
involved in the cell death to achieve maximum effect from PS. Mitochondria 
are the most crucial organelles in the cell due to their involvement of 
apoptotic cell death. Mitochondria possess a unique property: a higher trans 
membrane potential in cancerous cells compared to normal cells. 
Compounds bearing positive charge accumulate specifically in cancerous 
cells compared to normal cells. In the part-I of mitochondrial delivery a TPP-
OH that absorbs around 650 nm was used as a PS and Rh B or acridine 
orange were used as cations. Conjugation of photosensitizer to cationic dyes 
improved the uptake into mitochondria with TPP-Rh 8 times higher in cellular 
uptake compared to unconjugated porphyrin TPP-OH. When irradiated with 
400-800 nm broad band light at 3mW/cm2, TPP-Rh showed IC50 of 3.95 µM; 
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this was much higher when compared to TPP-OH, which was > 20 µM. The 
higher cellular uptake could be one of the major reasons for the higher 
phototoxicity. Subcellular localization studies suggested TPP-Rh localized in 
mitochondria. A colocalization study with a MG, a known mitochondrial 
probe, and superimposition of signal from both the dyes showed an overlap. 
The compound TPP-AO showed some dark toxicity at 10 µM and showed 
mitochondrial and nucleosomal staining.  
In the part-II of mitochondrial delivery CMP which absorbs around near IR 
(690nm) and cations RhB and tPP. All the conjugates showed similar 
photophysical properties as the unconjugated porphyrin. Studies showed 
less aggregation of the cations in DMSO. Electron transfer was observed in 
CMP-Rh from RhB to CMP but this did not affect the SO generating 
capability. All the conjugates showed comparable SO generation to CMP-
OH. In vitro uptake of CMP-tPP was the highest with 14 folds higher than 
CMP-OH and followed by uptake of CMP-Rh, which was 7 times. No dark 
toxicity was observed up to 5 µM concentration with any of the dyes. CMP-
tPP showed the highest phototoxicity under the above irradiation conditions 
with an IC50 of 0.9 µM and followed by CMP-(tPP)2 with an IC50 of 1.67 µM 
and then CMP-Rh with an IC50 of 2.36 µM. Subcellular localization of CMP-
Rh was closest to Rh-123 which is a mitochondrial localizing dye. CMP-tPP 
did not show any mitochondrial localization. CMP-(tPP)2 showed 
mitochondrial localization to some extent.   
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In vivo studies with CMP-tPP so far showed 3 times higher uptake in tumor 
and other tissue in comparison to our earlier studied compound IY69. 
In a second approach of targeted delivery, prodrugs of porphyrin and        
anti-cancer drugs attached via a SO cleavable linker were biologically 
evaluated. The SO generated in PDT can show its action within a radius of 
20 nm and is short lived (40 ns). That means PDT cannot generate a 
bystander effect. In the case of the CMP-L-CA4 prodrug, once the anti 
cancer drug was released, it showed a bystander effect. Only half of each 
well of 24 well plate was irradiated. Up on irradiation, the released CA4 not 
only killed the cells in the irradiated portion but also caused bystander effect 
in the unirradiated portion. In vivo tumor efficacy showed interesting results. 
CMP-L-CA4 + CA4 at 4 µM each in absence of light showed no significant 
effect. But upon irradiation, CMP-L-CA4 at 2 µM showed the highest tumor 
suppression of all the groups due to the release of CA4. CMP-NCL-CA4 + 
CA4 2 µM each in the presence of light showed better anti tumor activity than 
the untreated group. This effect is assumed to be from PDT as CA4 itself did 
not show any anti tumor effect at our treatment conditions.  
Overall, these studies indicate that by conjugating PS to lipophilic cation     
Rh B via a short saturated hydrocarbon linker or conjugating a PS with an 
anti-cancer drug via a SO cleavable linker, compounds can be  specifically 
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